Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors.

This is the author's manuscript

Original Citation:

Availability:

This version is available http://hdl.handle.net/2318/1700250 since 2019-04-29T10:47:36Z

Published version:

DOI:10.1530/EJE-16-0467

Terms of use:
Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
Management of adrenal incidentalomas
- a European Society of Endocrinology Clinical Practice
Guideline in collaboration with the European Network for the Study of Adrenal Tumors

Martin Fassnacht¹,², Wiebke Arlt³,⁴, Irina Bancos³,⁴,⁵, Henning Dralle⁶,
John Newell-Price⁷,⁸, Anju Sahdev⁹, Antoine Tabarin¹⁰, Massimo Terzolo¹¹,
Stylianos Tsagarakis¹², Olaf M. Dekkers¹³,¹⁴

¹ Department of Internal Medicine I, Division of Endocrinology and Diabetes, University
Hospital, University of Würzburg, Würzburg Germany
² Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany.
³ Institute of Metabolism & Systems Research, University of Birmingham, Birmingham, B15
TT, UK
⁴ Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners,
Birmingham, B15 2TH, UK
⁵ Division of Endocrinology, Metabolism, Nutrition and Diabetes, Mayo Clinic, Rochester, MN,
USA
⁶ Department of General, Visceral, and Vascular Surgery, Martin-Luther-University Halle-
Wittenberg, Halle (Saale), Germany
⁷ Department of Oncology and Metabolism, Medical School, University of Sheffield, S10 2RX,
UK
⁸ Endocrine Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation
Trust, S10 2JF, UK
⁹ Department of Imaging, St Bartholomew's Hospital, Barts Health, London, EC1A 7BE, UK
¹⁰ Department of Endocrinology and INSERM U862, University and CHU of Bordeaux, France
¹¹ Internal Medicine 1, Department of Clinical and Biological Sciences, University of Turin, Italy
¹² Department of Endocrinology, Diabetes and Metabolism, Evangelismos Hospital, Athens,
Greece
¹³ Departments of Clinical Epidemiology and Internal Medicine, Leiden University Medical
Centre, Leiden, The Netherlands
¹⁴ Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.
Abstract
By definition, an adrenal incidentaloma is an asymptomatic adrenal mass detected on imaging not performed for suspected adrenal disease. In most cases, adrenal incidentalomas are non-functioning adrenocortical adenomas, but may also represent conditions requiring therapeutic intervention including adrenocortical carcinoma, pheochromocytoma, hormone-producing adenoma or metastasis. The purpose of this guideline is to provide clinicians with best possible evidence-based recommendations for clinical management of patients with adrenal incidentalomas based on the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system.

We predefined four main clinical questions crucial for the management of adrenal incidentaloma patients, addressing these four with systematic literature searches: A) How to assess risk of malignancy?; B) How to define and manage low level autonomous cortisol secretion, the so-called "subclinical" Cushing syndrome?; C) Who should have surgical treatment and how should it be performed?; D) What follow-up is indicated if the adrenal incidentaloma is not surgically removed?

Selected Recommendations: 1) At the time of initial detection of an adrenal mass establishing whether the mass is benign or malignant is an important aim to avoid cumbersome and expensive follow-up imaging in those with benign disease. 2) To exclude cortisol excess a 1-mg overnight dexamethasone suppression test should be performed (applying a cutoff value of serum cortisol ≤ 50 nmol/l (1.8 µg/dl)). 3) For patients without clinical signs of overt Cushing's syndrome but serum cortisol levels post 1mg dexamethasone > 140 nmol/l (> 5 µg/dl) we propose the term ‘autonomous cortisol secretion’. 4) All patients with '(possible) autonomous cortisol secretion' should be screened for hypertension and type 2 diabetes mellitus, to ensure these are appropriately treated. 5) Surgical treatment should be considered in an individualized approach in patients with 'autonomous cortisol secretion' who also have comorbidities that are potentially related to cortisol excess. 6) In principle, the appropriateness of surgical intervention should be guided by the likelihood of malignancy, the presence and degree of hormone excess, age, general health and patient preference. 7) Surgery is not usually indicated in patients with an asymptomatic, non-functioning unilateral adrenal mass and obvious benign features on imaging studies. We provide guidance on which surgical approach should be considered for adrenal masses with radiological findings suspicious of malignancy. Furthermore, we offer recommendations for the follow-up of patients with adrenal incidentaloma who do not undergo adrenal surgery, for those with bilateral incidentalomas, for patients with extra-adrenal malignancy and adrenal masses, and for young and elderly patients with adrenal incidentalomas.
1. Summary of Recommendations*

1.1 General remarks

R.1.1 We recommend that patients with adrenal incidentalomas are discussed in a multidisciplinary expert team meeting, if at least one of the following criteria is met:
- Imaging is not consistent with a benign lesion.
- There is evidence of hormone excess (including “autonomous cortisol secretion”).
- Evidence of significant tumor growth during follow-up imaging.
- Adrenal surgery is considered.

1.2 Assessment of the risk of malignancy

R.2.1 We recommend aiming to establish if an adrenal mass is benign or malignant at the time of initial detection.

R.2.2 We recommend that all adrenal incidentalomas undergo an imaging procedure to determine if the mass is homogeneous and lipid-rich and therefore benign (XOOO). For this purpose, we primarily recommend the use of non-contrast CT (XOOO).

R.2.3 We suggest that if the non-contrast CT is consistent with a benign adrenal mass (Hounsfield units ≤ 10) that is homogeneous and smaller than 4 cm no further imaging is required (XOOO).

R.2.4 If the adrenal mass is indeterminate on non-contrast CT and the results of the hormonal work-up do not indicate significant hormone excess, three options should be considered by a multidisciplinary team acknowledging the patient’s clinical context: immediate additional imaging with another modality, interval imaging in 6 to 12 months (non-contrast CT or MRI), or surgery without further delay.

R.2.5 We recommend against the use of an adrenal biopsy in the diagnostic work-up of patients with adrenal masses unless there is a history of extra-adrenal malignancy and additional criteria are fulfilled (see R6.3.5).

1.3 Assessment for hormone excess

R.3.1 We recommend that every patient with an adrenal incidentaloma should undergo careful assessment including clinical examination for symptoms and signs of adrenal hormone excess.

R.3.2 We recommend that all patients with adrenal incidentalomas undergo a 1-mg overnight dexamethasone suppression test to exclude cortisol excess (XXOO).

R.3.3 We suggest interpretation of the results of the 1-mg overnight dexamethasone test as a continuous rather than categorical (yes/no) variable (XOOO). However, we recommend

* The recommendations are worded as recommend (strong recommendation) and suggest (weak recommendation). The quality of evidence behind the recommendations is classified as low very low (⊕ΟΟΟ), low (⊕⊕ΟΟ), moderate (⊕⊕⊕Ο) and strong (⊕⊕⊕⊕). See further Section 3.4.
using serum cortisol levels post dexamethasone ≤ 50 nmol/l (≤ 1.8 µg/dl) as a diagnostic criterion for the exclusion of autonomous cortisol secretion (XXOO).

R.3.4 We suggest that post dexamethasone serum cortisol levels between 51 and 140 nmol/l (1.9 - 5.0 µg/dl) should be considered as evidence of ‘possible autonomous cortisol secretion’ and cortisol levels post dexamethasone > 140 nmol/l (> 5.0 µg/dl) should be taken as evidence of ‘autonomous cortisol secretion’. Additional biochemical tests to confirm cortisol secretory autonomy and assess the degree of cortisol secretion might be required. However, for the clinical management the presence of potentially cortisol-related comorbidities and age of the patient are of major importance.

R.3.5 We recommend against considering ‘autonomous cortisol secretion’ as a condition with a high risk for the development of overt Cushing’s syndrome (XXOO).

R.3.6 We recommend screening patients with ‘possible autonomous cortisol secretion’ or ‘autonomous cortisol secretion’ for hypertension and type 2 diabetes mellitus (XOOO) and suggest offering appropriate treatment of these conditions.

R.3.7 We suggest screening patients with ‘autonomous cortisol secretion’ for asymptomatic vertebral fractures (XOOO) and to consider appropriate treatment of these conditions (XOOO).

R.3.8 We suggest an individualized approach to consider patients with ‘autonomous cortisol secretion’ due to a benign adrenal adenoma and comorbidities potentially related to cortisol excess for adrenal surgery (XOOO). Age, degree of cortisol excess, general health, comorbidities and patient’s preference should be taken into account. In all patients considered for surgery, ACTH-independency of cortisol excess should be confirmed.

R.3.9 We recommend excluding pheochromocytoma by measurement of plasma free metanephrines or urinary fractionated metanephrines.

R.3.10 In patients with concomitant hypertension or unexplained hypokalemia, we recommend the use of the aldosterone / renin ratio to exclude primary aldosteronism.

R.3.11 We suggest measurement of sex hormones and steroid precursors in patients with clinical or imaging features suggestive of adrenocortical carcinoma.

1.4 Surgical treatment

R.4.1 We recommend adrenalectomy as the standard of care for unilateral adrenal tumors with clinically significant hormone excess.

R.4.2 We recommend against performing surgery in patients with an asymptomatic, non-functioning unilateral adrenal mass and obvious benign features on imaging studies (XOOO).

R.4.3 We suggest performing laparoscopic adrenalectomy in patients with unilateral adrenal masses with radiological findings suspicious of malignancy and a diameter ≤ 6 cm, but without evidence of local invasion (XOOO).
R.4.4 We recommend performing open adrenalectomy for unilateral adrenal masses with radiological findings suspicious of malignancy and signs of local invasion (XOOO).

R.4.5 We suggest an individualized approach in patients that do not fall in one of the above-mentioned categories (XOOO).

R.4.6 We recommend perioperative glucocorticoid treatment at major surgical stress doses as recommended by guidelines, in all patients undergoing surgery for an adrenal tumor where there is evidence of ‘(possible) autonomous cortisol secretion’, i.e. who do not suppress to <50 nmol/L after 1mg dexamethasone overnight.

1.5 Follow-up of patients not undergoing adrenal surgery after initial assessment

R.5.1 We suggest against further imaging for follow-up in patients with an adrenal mass < 4cm with clear benign features on imaging studies (XOOO).

R.5.2 In patients with an indeterminate adrenal mass (by imaging) opting not to undergo adrenalectomy following initial assessment, we suggest a repeat non-contrast CT or MRI after 6-12 months to exclude significant growth (XOOO). We suggest surgical resection if the lesion enlarges by more than 20% (in addition to at least a 5 mm increase in maximum diameter) during this period. If there is growth of the lesion below this threshold, additional imaging after 6-12 months should be performed.

R.5.3 We suggest against repeated hormonal work-up in patients with a normal hormonal work-up at initial evaluation unless new clinical signs of endocrine activity appear or there is worsening of comorbidities (e.g. hypertension and type 2 diabetes) (XOOO).

R.5.4 In patients with ‘autonomous cortisol secretion’ without signs of overt Cushing’s syndrome, we suggest annual follow-up re-assessment for cortisol excess and careful assessment of comorbidities potentially related to cortisol excess (XOOO). Based on the outcome of this evaluation the potential benefit of surgery should be considered.

1.6 Special circumstances

1.6.1 Patients with bilateral adrenal incidentalomas

R.6.1.1 We recommend that for patients with bilateral adrenal masses each adrenal lesion is assessed at the time of initial detection according to the same imaging protocol as for unilateral adrenal masses to establish if either or both masses are benign or malignant.

R.6.1.2 We recommend that all patients with bilateral adrenal incidentalomas should undergo clinical and hormonal assessment identical to that in patients with unilateral adrenal incidentaloma. The same applies for the assessment of comorbidities that might be related to autonomous cortisol secretion. In addition, 17-hydroxyprogesterone should be measured to exclude congenital adrenal hyperplasia, and testing for adrenal
insufficiency should be considered, if suspected on clinical grounds or if imaging
suggests bilateral infiltrative disease or hemorrhages.

R.6.1.3 We suggest that for patients with bilateral incidentaloma the same recommendations
regarding the indication for surgery and follow-up are used as for patients with
unilateral adrenal incidentalomas.

R.6.1.4 We suggest that in patients with bilateral adrenal masses bilateral adrenalectomy is
not performed for ACTH-independent ‘autonomous cortisol secretion’ without clinical
signs of overt Cushing’s syndrome. In selected patients, a unilateral adrenalectomy of
the dominant lesion might be considered using an individualized approach considering
age, degree of cortisol excess, general condition, comorbidities and patient
preference.

1.6.2 Adrenal incidentalomas in young or elderly patients

R.6.2.1 We recommend urgent assessment of an adrenal mass in children, adolescents,
pregnant women and adults < 40 years of age because of a higher likelihood of
malignancy.

R.6.2.2 We suggest the use of MRI rather than CT in children, adolescents, pregnant women
and adults < 40 years of age if dedicated adrenal imaging is required.

R.6.2.3 We recommend that the management of patients with poor general health and a high
degree of frailty be kept in proportion to potential clinical gain.

1.6.3 Patients with a newly diagnosed adrenal mass and a history of extra-
adrenal malignancy

R.6.3.1 We recommend measurement of plasma or urinary metanephrines to exclude
pheochromocytoma in patients with extra-adrenal malignancy with an indeterminate
mass, even if the adrenal mass is likely to be a metastasis. We suggest additional
hormonal work-up based on an individualized approach.

R.6.3.2 We suggest that in patients with a history of extra-adrenal malignancy FDG-PET/CT,
performed as part of investigations for the underlying malignancy, can replace other
adrenal imaging techniques.

R.6.3.3 We recommend that in patients with a history of extra-adrenal malignancy adrenal
lesions characterized as benign (see also R.2.3) by non-contrast CT require no further
specific adrenal imaging follow-up.

R.6.3.4 For indeterminate lesions in patients with a history of extra-adrenal malignancy, we
recommend imaging follow-up assessing the potential growth of the lesion at the same
interval as imaging for the primary malignancy. Alternatively, FDG-PET/CT, surgical
resection or a biopsy (see also R.6.3.5) can be considered.

R.6.3.5 We suggest performing a biopsy of an adrenal mass only if all of the following criteria
are fulfilled: (i) the lesion is hormonally inactive (in particular, a pheochromocytoma
has been excluded), (ii) the lesion has not been conclusively characterized as benign by imaging, and (iii) management would be altered by knowledge of the histology.

R.6.3.6 We recommend assessment of residual adrenal function in patients with large bilateral adrenal metastases.
2. Adrenal Incidentaloma – Clinical presentation and terminology

2.1 Definition, etiology and epidemiology of adrenal incidentalomas

An adrenal incidentaloma is an adrenal mass detected on imaging not performed for suspected adrenal disease. By this strict definition, the imaging study is not done for symptoms related to adrenal hormone excess (e.g. pheochromocytoma, Cushing’s or Conn’s syndrome) or an otherwise suspected adrenal mass, but rather for the evaluation of symptoms that are not obviously related to an adrenal problem, such as abdominal or back pain or kidney stones. Similarly, screening imaging in patients with a hereditary syndrome leading to adrenal tumors is outside the definition of an adrenal incidentaloma. In addition, adrenal masses discovered on an imaging study performed during tumor evaluation for extra-adrenal malignancies (“tumor staging” or follow-up) do not meet the strict definition of adrenal incidentaloma. However, as this is a clinically frequent scenario, we will address this in a specific chapter (see 5.6.4).

Previous recommendations and reviews (Barzon, 1999 #112; Barzon, 2003 #38; Cawood, 2009 #35; Favia, 2000 #114; Grumbach, 2003 #39; Kloos, 1995 #36; Mansmann, 2004 #40; Tabarin, 2008 #59; Terzolo, 2011 #33; Young, 2007 #43; Zeiger, 2009 #57; Zeiger, 2009 #58; Young, 2000 #147) have not considered adrenal incidentalomas smaller than 1 cm. Although this cut-off is obviously somewhat arbitrary, we agree with this approach and would perform additional diagnostic work-up only in lesions ≥ 1 cm unless clinical signs and symptoms suggestive of adrenal hormone excess are present.

The etiology of adrenal incidentalomas varies and includes benign and malignant lesions derived from the adrenal cortex, the medulla or of extra-adrenal origin. The reported frequency varies, depending on the context of the study and inclusion size criteria (see Table 1). Some authors conclude, however, that the prevalence of malignant and functional lesions is likely to be overestimated (Cawood, 2009 #35), mainly because the prevalence of malignancy in surgical series is usually higher than in series including all patients presenting with an adrenal mass. There is, however, clear evidence that the vast majority of adrenal incidentalomas are benign adrenocortical adenomas.

The incidence and prevalence of adrenal incidentalomas can only be extrapolated from imaging or autopsy studies. Autopsy studies suggest a prevalence of clinically unapparent adrenal masses of around 2% (range 1.0-8.7%), which increases with age {Kloos, 1995 #36; Mansmann, 2004 #40; Grumbach, 2003 #39}. Radiological studies report a frequency of around 3% in the age of 50 years, which increases up to 10% in the elderly {Kloos, 1995 #36; Mansmann, 2004 #40; Grumbach, 2003 #39; Barzon, 2003 #38; Mantero, 2000 #37; Bovio, 2006 #45; Benitah, 2005 #44}. In childhood, adrenal incidentalomas are extremely rare.
Table 1: Adrenal incidentalomas - frequency of the different underlying tumor types (adapted according {Terzolo, 2011 #33})

<table>
<thead>
<tr>
<th>Tumor entity</th>
<th>Median (%)</th>
<th>Range (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Series including all patients with an adrenal mass</strong>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adenoma</td>
<td>80</td>
<td>33-96</td>
</tr>
<tr>
<td>Non-functioning</td>
<td>75</td>
<td>71-84</td>
</tr>
<tr>
<td>Autonomously cortisol-secreting</td>
<td>12</td>
<td>1.0-29</td>
</tr>
<tr>
<td>Aldosterone-secreting</td>
<td>2.5</td>
<td>1.6-3.3</td>
</tr>
<tr>
<td>Pheochromocytoma</td>
<td>7.0</td>
<td>1.5-14</td>
</tr>
<tr>
<td>Adrenocortical carcinoma</td>
<td>8.0</td>
<td>1.2-11</td>
</tr>
<tr>
<td>Metastasis</td>
<td>5.0</td>
<td>0-18</td>
</tr>
<tr>
<td><strong>Surgical series</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adenoma</td>
<td>55</td>
<td>49-69</td>
</tr>
<tr>
<td>Non-functioning</td>
<td>69</td>
<td>52-75</td>
</tr>
<tr>
<td>Cortisol-secreting</td>
<td>10</td>
<td>1.0-15</td>
</tr>
<tr>
<td>Aldosterone-secreting</td>
<td>6.0</td>
<td>2.0-7.0</td>
</tr>
<tr>
<td>Pheochromocytoma</td>
<td>10</td>
<td>11-23</td>
</tr>
<tr>
<td>Adrenocortical carcinoma</td>
<td>11</td>
<td>1.2-12</td>
</tr>
<tr>
<td>Myelolipoma</td>
<td>8.0</td>
<td>7.0-15</td>
</tr>
<tr>
<td>Cyst</td>
<td>5.0</td>
<td>4.0-22</td>
</tr>
<tr>
<td>Ganglioneuroma</td>
<td>4.0</td>
<td>0-8.0</td>
</tr>
<tr>
<td>Metastasis</td>
<td>7.0</td>
<td>0-21</td>
</tr>
</tbody>
</table>

* Data from references: {Barzon, 2003 #38; Kloos, 1995 #36; Mantero, 2000 #37}
** Data from references: {Barzon, 2003 #38; Kloos, 1995 #36; Mantero, 2000 #37; Bernini, 2002 #41; Cawood, 2009 #35; Lam, 2002 #42; Mansmann, 2004 #40; Young, 2007 #43}

Due to the nature of these studies a selection bias is very probable (the populations studied not reflecting a random sample of all patients with an adrenal incidentalomas) and most likely leads to an overestimation of the frequency of some tumor entities.

2.2. Remarks on terminology

As already discussed above, the term 'adrenal incidentaloma' can be defined by very restrictive criteria, but is sometimes used in a much broader sense, referring to any adrenal mass. Therefore, in the guideline we frequently speak of adrenal masses or lesions.

Another term, which is widely used in the literature in the context of adrenal incidentaloma, is 'subclinical Cushing's syndrome' {Ross, 1994 #131}. This term aims to define patients with biochemical evidence of cortisol excess, but without the so-called "specific" clinical signs of Cushing's syndrome (mainly the lack of catabolic features, like myopathy and skin fragility). There is, however, clear evidence that patients with clinically unapparent cortisol excess very rarely develop Cushing's syndrome {Barzon, 1999 #112; Barzon, 2003 #38; Bernini, 2005 #137; Fagour, 2009 #136; Libe, 2002 #123; Terzolo, 2005 #135; Terzolo, 1998 #134; Nieman, 2015 #142} and that this condition is different from overt Cushing's syndrome, which is clearly associated with severe morbidity and elevated mortality {Dekkers, 2013 #130; Lacroix, 2015 #125}.
Nevertheless, there is some evidence that this low-grade autonomous cortisol excess might be associated with certain comorbidities (see Table 2). Thus, the panel unanimously decided to avoid the term “subclinical Cushing’s syndrome” and to use instead the term “autonomous cortisol secretion” in the context of an adrenal incidentaloma throughout the guideline text (for the exact definition see chapter 5.3).

Although the term “laparoscopic adrenalectomy” is actually reserved for operations that use a transperitoneal approach and should be distinguished from the term retroperitoneoscopic adrenalectomy, this never gained general acceptance. Therefore, in this guideline we use the term “laparoscopic adrenalectomy” to refer to minimally invasive approaches including retroperitoneoscopic surgery.

Table 2: Comorbidities possibly associated with adrenal incidentalomas with ‘autonomous cortisol secretion’

<table>
<thead>
<tr>
<th>Comorbidities</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>{Terzolo, 2005 #146;Terzolo, 2005 #135;Tauchmanova, 2002 #143;Emral, 2003 #144;Bernini, 2003 #164;Morelli, 2010 #163;Rossi, 2000 #162}</td>
</tr>
<tr>
<td>Glucose intolerance / type 2 diabetes mellitus</td>
<td>{Terzolo, 2005 #146;Terzolo, 2005 #135;Tauchmanova, 2002 #143;Emral, 2003 #144;Reincke, 1996 #166;Bernini, 2003 #164;Di Dalmazi, 2012 #12;Fernandez-Real, 1998 #165;Morelli, 2010 #163;Rossi, 2000 #162}</td>
</tr>
<tr>
<td>Obesity</td>
<td>{Terzolo, 2005 #146;Terzolo, 2005 #135;Tauchmanova, 2002 #143;Emral, 2003 #144}</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>{Terzolo, 2005 #146;Terzolo, 2005 #135;Tauchmanova, 2002 #143;Giordano, 2010 #6;Rossi, 2000 #162}</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>{Hadjidakis, 2003 #145;Chiodini, 2004 #18;Chiodini, 2009 #53;Chiodini, 2010}</td>
</tr>
</tbody>
</table>
2.3. Short overview on adrenal imaging

For the differentiation of malignant from benign adrenal tumors, there are three main imaging techniques in current use: computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography with $^{18}$F-2-deoxy-D-glucose (mostly combined with CT; FDG-PET/CT). CT and MRI are techniques mainly aiming to identify benign lesions, therefore representing tools designed for the exclusion of adrenal malignancy (Peppercorn, 1998 #168; Caoili, 2002 #80; Blake, 2006 #93; Ilias, 2007 #167). Conversely, FDG-PET/CT is mainly used for the detection of malignant disease (Mackie, 2006 #185; Groussin, 2009 #100; Deandreis, 2011 #184).

CT has a high spatial and quantitative contrast resolution, which allows assessment of tissue density by measuring X-ray absorption of tissues. This allows calculation of tissue attenuation or tissue density values, which are measured in Hounsfield units (HU) and quantify X-ray absorption of tissues compared to water, which is conventionally allocated a HU value of 0. For non-contrast (or ‘unenhanced’) CT, HU of ≤ 10 is the most widely used threshold attenuation value for the diagnosis of a lipid-rich, benign adrenal adenoma (Boland, 1998 #201). However, on non-contrast CT, some 30% of benign adenomas have an attenuation value of > 10 HU and are considered lipid-poor, overlapping in density with malignant lesions and pheochromocytomas (Caoili, 2000 #202; Pena, 2000 #171; Zhang, 2012 #183).

Contrast-enhanced washout CT utilizes the unique perfusion pattern of adenomas. Adenomas take up intravenous CT contrast rapidly, but also have a rapid loss of contrast - a phenomenon termed ‘contrast enhancement washout’. It is assumed that malignant adrenal lesions usually enhance rapidly but demonstrate a slower washout of contrast medium. This washout phenomenon can be quantified by ‘contrast washout values’, which involve lesion attenuation measurements at specific time points acquired in a dedicated adrenal CT: prior to injection of contrast medium ($H_{\text{nativ}}$), at 60 seconds following injection of contrast medium ($H_{\text{max}}$) and then at 10 or 15 minutes after contrast injection. This allows calculation of the relative contrast enhancement washout ($=100x(H_{\text{max}}-H_{\text{10/15min}})/H_{\text{max}}$) and absolute contrast enhancement washout ($=100x(H_{\text{max}}-H_{\text{10/15min}})/(H_{\text{max}}-H_{\text{nativ}})$). A relative washout > 40% and an absolute washout > 60% is assumed to suggest that an adrenal lesion is benign (Pena, 2000 #171; Dunnick, 2002 #205; Szolar, 1998 #174; Young, 2011 #182).

MRI is a non-ionising radiation based imaging modality utilizing weak radio wave signals emitted by body tissues when the body is placed in a strong magnetic field and radio frequency pulses are applied. The advantages of MRI over CT are its lack of radiation exposure, lack of
iodine-based contrast media and its superior tissue contrast resolution. For the differentiation of
benign and malignant adrenal masses the MRI technique of chemical-shift imaging is most
commonly used {McNicholas, 1995 #68; Sahdev, 2004 #175; Korobkin, 1996 #177; Korobkin,
1996 #178; Haider, 2004 #181; Young, 2011 #182}. Chemical shift imaging relies on the fact
that, within magnetic fields, protons in water vibrate at a slightly different frequency than
protons in lipid. As a result, water and fat protons oscillate in and out of phase with respect to
one another. By selecting appropriate sequencing parameters, separate images can be
generated with water and fat protons oscillating in-phase or out-of-phase to each other. Adrenal
adenomas with a high content of intracellular lipid usually lose signal intensity on out-of-phase
images compared to in-phase images, whereas malignant lesions and pheochromocytomas
(but also lipid-poor adrenal adenomas) that all lack intracellular lipid remain unchanged {Haider,
2004 #181; Dunnick, 2002 #205; Bharwani, 2011 #212}. Simple visual assessment of signal
intensity loss is diagnostic in most cases but quantitative methods may be useful in less clear
cut cases. Quantitative analysis can be made using the adrenal-to-spleen signal ratio and the
signal intensity index. MR signal intensity units are arbitrary units, unlike CT, and therefore are
subject to numerous technical variations.

18F-FDG-PET is a nuclear medicine modality that provides quantitative tomographic images
after intravenous injection of a beta-radiation emitting radiotracer (18-Fluorine) used to label 2-
deoxy-D-glucose rendering Fluoro-deoxyglucose (18F-FDG). Both glucose and deoxyglucose
enter cells via cell glucose transporters and undergo phosphorylation but while glucose
undergoes further enzymatic breakdown, deoxyglucose becomes trapped in intracellular
compartments. Cancer cells have an increased requirement for glucose and, therefore, take up
more glucose and deoxyglucose than normal cells {Becherer, 2001 #188}. However, 18F-FDG
is not a specific marker for cancer cells but a marker only for increased glucose metabolism
thus uptake can also be increased in cells with an increased energy requirement due to
conditions other than cancer. Quantitative measurement of 18F concentrations within tissues
provides the most commonly used clinical measurement index, standard uptake value (SUV),
which compares the intensity of uptake of 18F in the adrenal lesion to the average uptake of
whole body. SUV values have been utilized to differentiate between benign from malignant
adrenal lesions. FDG-PET has a high sensitivity for detection of metabolic changes but its
spatial resolution for anatomical localization is poor. The solution is a hardware fusion between
PET and CT (PET/CT) allowing simultaneous acquisition of PET and CT data. In clinical
practice this involves injecting patients with 18F-FDG tracers at least one hour prior to the start
of combined PET/CT. Once post processing is complete, PET and CT data can be viewed
separately, side-by-side or as a fused images {Vogel, 2004 #214}.

Other potentially emerging imaging techniques (e.g. metomidate-based adrenal imaging) are
not yet clinically widely available and, therefore, will not be discussed in this guideline.
2.4. Remarks on the difficulties with hormonal testing

Hormone assessment is crucial in the context of the work-up for an adrenal incidentaloma. However, there are several pitfalls that have to be considered (e.g. daily rhythm, sex-/age-dependency, limitations of assays, drug interactions). Furthermore, normal ranges vary substantially, depending on the method used, so it is essential to interpret test results in the context of the appropriate reference range. Due to space restrictions we refer to other guidelines that have addressed these issues in more detail {Nieman, 2008 #47; Lenders, 2014 #48}. 
3. Methods

3.1. Guideline working group

This guideline was developed by The European Society of Endocrinology (ESE) in collaboration with the European Network for the Study of Adrenal Tumours (ENSAT), supported by CBO (Dutch Institute for healthcare improvement). The chairs of the working group Martin Fassnacht (clinical) and Olaf Dekkers (methodology) were appointed by the ESE Clinical Committee. The other members were suggested by the chairs and approved by the Clinical Committee of ESE: endocrinologists (Wiebke Arlt (UK), Irina Bancos (USA), John Newell-Price (UK), Antoine Tabarin (France), Massimo Terzolo (Italy), Stylianos Tsagarakis (Greece), a radiologist (Anju Sahdev (UK), and an endocrine surgeon (Henning Dralle (Germany)). Irina Bancos served as representative of The Endocrine Society USA. The working group had three in-person meetings (December 2013, October 2014, and June 2015) and communicated by phone and email. Consensus was reached upon discussion; minority positions were taken into account in the rationale behind recommendations. Prior to the process, all participants completed conflict of interest forms.

3.2 Target group

This guideline was developed for healthcare providers of patients with adrenal incidentalomas, ie, endocrinologists, radiologists, surgeons, and specialists in internal medicine. However, general practitioners might also find the guideline useful, as might our patients. In addition, the guideline document can serve as guidance for patient information leaflets. A draft of the guideline was reviewed by four experts in the field (see “Acknowledgment” section) and has been submitted for comments by ESE and ENSAT members. All comments and suggestions were then discussed and implemented as appropriate by the panel.

3.3 Aims

The overall purpose of this guideline is to provide clinicians with practical guidance for the management of patients with adrenal incidentalomas.

3.4 Summary of methods used for guideline development

The methods used have been described in more detail previously {Bollerslev, 2015 #46}. In short, the guideline used GRADE (Grading of Recommendations Assessment, Development and Evaluation) as a methodological base. The first step was to define clinical question(s) (see section 3.5), the second being a systematic literature search (see Section 3.6). After including
relevant articles, we 1), estimated an average effect for specific outcomes (if possible), and 2),
rated the quality of the evidence. The quality of evidence behind the recommendations is
classified as very low (⊕ΟΟΟ), low (⊕⊕ΟΟ), moderate (⊕⊕⊕Ο) and strong (⊕⊕⊕⊕). Evidence
tables are provided in Supplemental file II.

For the recommendations we took into account: 1) quality of the evidence, 2) balance of
desirable and undesirable outcomes, 3) values and preferences (patient preferences, goals for
health, costs, management inconvenience, feasibility of implementation, etc). {Hammarstedt,
2010 #126;Andrews, 2013 #133}. The recommendations are worded as recommend (strong
recommendation) and suggest (weak recommendation). Formal evidence syntheses were
performed and graded only for recommendations addressing our initial questions. Additional
recommendations based on good practice were not graded {Ferreira, 2005 #128}.

Recommendations were derived from majority consensus of the guideline development
committee, but if members had substantive disagreements, this is acknowledged in the
manuscript. For transparency, all recommendations provided are accompanied by text
explaining why specific recommendations were made.

### 3.5. Clinical question, eligibility criteria and endpoint definition

At the beginning of the guideline development process, the panel agreed on the four most
important clinical questions in the management of patients with adrenal incidentalomas (Table
3), for which a detailed literature search was subsequently performed.

### 3.6 Description of search and selection of literature

A literature search in electronic medical databases was performed for all four clinical questions
separately. Of note, the approach for clinical question 1 (assessment of the risk of malignancy)
differed as the search, study selection and also the evidence synthesis was performed in the
context of a formal systematic review and meta-analysis published separately from the current
guideline. For all four clinical questions details of the yield of the search are shown in Table 3.
In summary, we included 37 studies for clinical question 1 (with 18 fulfilling the criteria for
inclusion in the meta-analysis), twelve studies for clinical question 2a (biochemical profile in
adrenal incidentaloma), four studies for clinical question 2b (therapeutic approach in mild
glucocorticoid excess), nine studies for clinical question 3 (surgery) and ten studies plus one
relevant systematic review for clinical question 4 (follow-up).
### Table 3: Overview of the key clinical questions and predefined outcome parameters

<table>
<thead>
<tr>
<th>Clinical Question</th>
<th>Predefined selection criteria and key outcome parameters</th>
<th>Metrics of the literature search</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Question 1a)</strong></td>
<td>What is the most accurate diagnostic imaging procedure to determine whether an adrenal mass is benign in patients with unilateral or bilateral adrenal mass(es) on imaging with or without history of other malignant lesions?</td>
<td>5496 abstracts²</td>
</tr>
<tr>
<td></td>
<td>• Original studies on imaging in patients with incidentally discovered adrenal mass(es), including those undergoing staging for known extra-adrenal malignancy.</td>
<td>525 potentially relevant articles</td>
</tr>
<tr>
<td></td>
<td>• Diagnostic intervention: CT (non-contrast, contrast-enhanced, washout), MRI, FDG PET(CT)</td>
<td>37 studies included in systematic review, 18 in meta-analysis</td>
</tr>
<tr>
<td></td>
<td>• Reference standard: at least 50% of population had imaging-guided follow-up of any duration (for benign adrenal tumors), or histology after surgery or biopsy (for benign or malignant adrenal tumors)</td>
<td>Major reasons for exclusion of articles were lack of test accuracy data, inadequate or unclear reference standard and ineligible populations. Other reasons for exclusion data collection pre-1990, sample size &lt;10, &lt; 50% histology in malignant group, &gt;30% pheochromocytomas in malignant group, &gt;10% pheochromocytomas in benign group, no differentiation of children versus adults</td>
</tr>
<tr>
<td></td>
<td>• Reporting 2x2 contingency table data or at least two indices of diagnostic accuracy (sensitivity, specificity, negative or positive predictive value) and disease prevalence.</td>
<td>175 abstracts³</td>
</tr>
<tr>
<td></td>
<td>• Original studies on patients with adrenal masses undergoing an adrenal biopsy procedure</td>
<td>80 potentially relevant articles</td>
</tr>
<tr>
<td></td>
<td>• Outcomes: non-diagnostic rate, diagnostic accuracy data, complication rate</td>
<td>32 studies included in systematic review of at least one outcome.</td>
</tr>
<tr>
<td></td>
<td>• For studies included in the diagnostic accuracy analysis: 1) Reference standard: at least 50% of population either histology from adrenalectomy or autopsy, imaging follow up 3-12 months or clinical follow up of 2 years and 2) Reporting 2x2 contingency table data or at least two indices of diagnostic accuracy (sensitivity, specificity, negative or positive predictive value) and disease prevalence.</td>
<td>Diagnostic accuracy data included from 8 studies</td>
</tr>
<tr>
<td></td>
<td>• Major reasons for exclusion overall were: no outcomes of interest, fewer than 10 patients, abstract only, patient overlap.</td>
<td>Major reasons for exclusion from diagnostic accuracy analysis were: suboptimal reference standard and &gt;30% non-adenomas</td>
</tr>
<tr>
<td><strong>Question 1b)</strong></td>
<td>What is the diagnostic accuracy of adrenal biopsy?</td>
<td>8 studies included in systematic review of at least one outcome.</td>
</tr>
<tr>
<td></td>
<td>• Original studies on patients with adrenal masses undergoing an adrenal biopsy procedure</td>
<td>Diagnostic accuracy data included from 8 studies</td>
</tr>
<tr>
<td></td>
<td>• Outcomes: non-diagnostic rate, diagnostic accuracy data, complication rate</td>
<td>Major reasons for exclusion overall were: no outcomes of interest, fewer than 10 patients, abstract only, patient overlap.</td>
</tr>
<tr>
<td></td>
<td>• For studies included in the diagnostic accuracy analysis: 1) Reference standard: at least 50% of population either histology from adrenalectomy or autopsy, imaging follow up 3-12 months or clinical follow up of 2 years and 2) Reporting 2x2 contingency table data or at least two indices of diagnostic accuracy (sensitivity, specificity, negative or positive predictive value) and disease prevalence.</td>
<td>Major exclusions from diagnostic accuracy analysis were: suboptimal reference standard and &gt;30% non-adenomas</td>
</tr>
</tbody>
</table>

---

ESE and ENSAT guideline on adrenal incidentaloma v.21.3.2016
**Question 2a)**
Are certain biochemical profiles (see 4.2.1) associated with an increased cardiovascular, metabolic and fracture risk in patients with adrenal mass(es), in whom endocrine work-up for glucocorticoid excess was performed?

**Question 2b)**
Should surgery or a conservative/medical approach be recommended in patients with adrenal mass(es) and with defined biochemistry and cardiovascular, metabolic and fracture risk potentially indicative of mild glucocorticoid excess?

**Question 3)**
Should laparoscopic (=minimally-invasive) or open surgery be used for patients with non-metastatic adrenal masses suspected to be malignant?

**Question 4)**
What is the optimal follow-up in patients with an apparently benign adrenal incidentaloma in order to detect malignant transformation and/or development of overt hormone excess?
• 1 systematic review of 14 studies
• 10 additional cohort studies

For each question we searched separately for systematic reviews between 2000 and February 2014 in NHS Economic Evaluation Database (NHSEED), Cochrane Database of Systematic Reviews, and Database of Abstracts of Reviews of Effects. This revealed no relevant systematic review. Then, we searched for original articles in Medline published between 2000 and July 2014 (Question 3), October 2014 (Question 4), November 2014 (Question 2), and August 2015 (Question 1).

Summary of separately published meta-analysis {Dinnes, 2016 #246}.

Summary of separately published meta-analysis {Tamhane, 2016 #248}.
4. Summary and conclusions from systematic literature reviews

4.1 Assessment of the risk of malignancy (Question 1)

4.1.1 Assessment of the risk of malignancy by imaging (Question 1a)

The following paragraph represents a summary of a recent meta-analysis on the use of imaging for differentiating benign from malignant adrenal incidentalomas carried out with involvement of some of the guideline panel members {Dinnes, 2016 #246}. Studies were considered all studies of CT, MRI or FDG-PET in adults eligible if: 1) included patients underwent imaging for any indications other than investigation of suspected adrenal mass; 2) imaging follow up of any duration in the case of benign adrenal masses. Exclusion criteria are summarized in Table 3. The review looked separately at patients with true adrenal incidentaloma and patients with adrenal mass and a history of extra-adrenal malignancy.

We identified 37 studies for inclusion in the systematic review {Angelelli, 2013 #218;Marin, 2012 #224;Maurea, 2004 #88;Nunes, 2010 #101;Sandrasegaran, 2011 #105;Tessonnierr, 2008 #97;Vilar, 2008 #98;Burt, 1994 #63;Choi, 2013 #109;Frilling, 2004 #87;Lang, 2015 #120;McNicholas, 1995 #68;Porte, 1999 #76;Ream, 2015 #111;Schwartz, 1995 #69;Uemura, 2013 #111;Kunikowska, 2014 #121;Villar Del Moral, 2010 #104;Aksakal, 2013 #108;Bilbey, 1995 #131;Blake, 2006 #93;Boracchi, 1999 #74;Chung, 2001 #77;Groussin, 2009 #100;Gust, 2012 #106;Ichikawa, 1993 #61;Kamiyama, 2009 #219;Kebapci, 2003 #84;Launay, 2015 #226;Mayo-Smith, 1995 #67;Nwariaku, 2001 #79;Park, 2015 #115;Park, 2007 #96;Petersenn, 2015 #220;Remer, 2006 #94;Zettinig, 2004 #90;Zielonko, 2008 #99}, with only 18 of them fulfilling the criteria for inclusion in the actual meta-analysis {Angelelli, 2013 #218;Marin, 2012 #224;Maurea, 2004 #88;Nunes, 2010 #101;Sandrasegaran, 2011 #105;Tessonnierr, 2008 #97;Vilar, 2008 #98;Burt, 1994 #63;Choi, 2013 #109;Frilling, 2004 #87;Lang, 2015 #120;McNicholas, 1995 #68;Porte, 1999 #76;Ream, 2015 #111;Schwartz, 1995 #69;Uemura, 2013 #111;Kunikowska, 2014 #121;Villar Del Moral, 2010 #104}. No randomized studies comparing imaging tests were identified. Risk of bias ranged from low to high, with the majority having unclear or high risk of bias (mainly due to unclear population selection, retrospective selection of the diagnostic threshold and inadequate reference standards with resulting concerns of the applicability of results).

Five commonly used diagnostic thresholds were studied: (1) tumor density >10HU on non-contrast CT; (2) CT with delayed contrast media washout: absolute percentage washout and/or relative percentage washout at any washout percentage % or delay time on enhanced CT; (3) MRI chemical shift analysis: loss of signal intensity between in and out of phase...
images (including both qualitative and quantitative estimates of signal loss); and, for FDG-PET or PET-CT, (4) the maximum standardized uptake value (SUVmax), and (5) the ratio of SUVmax in the adrenal gland compared to the liver (adrenal liver ratio).

The 37 studies included were generally small with a median sample size of 45 (range 12 to 181). Of the 18 studies included in the formal meta-analysis, 7 addressed purely incidental adrenal masses and 11 studies focused on patients with known extra-adrenal malignancy.

Limited data (two studies with 102 true incidentalomas) suggest that CT density >10 HU has a high sensitivity for detection of adrenal malignancy (100%, 95% confidence interval 91-100%); meaning that adrenal masses with a density of ≤10 HU are unlikely to be malignant.

In patients with a history of extra-adrenal malignancy five studies evaluating the >10 HU cut-off as indicative of malignancy showed high sensitivity (93%) for detection of malignancy but variable specificity; this means that 7% of adrenal metastases were found to have a tumor density of ≤10 HU.

Disappointingly, all other estimates of test performance are based on small numbers of studies with very few patients and accompanying wide 95% confidence intervals, indicating much uncertainty in test performance for all other imaging markers. For true adrenal incidentalomas, two of three MRI studies reported slightly lower sensitivity and specificity than CT for measures of adrenal-liver and adrenal-spleen ratios and loss of signal intensity.

The performance of PET for adrenal liver ratio and SUVmax measures in the two included studies was not clearly better than CT. In patients with a history of extra-adrenal malignancy, only one study reported on CT contrast-enhanced washout tests, which showed very low sensitivity (16%). Four of the five studies of MRI used 1.5 Tesla machines and reported high sensitivity (89%-99%) for measures of adrenal-liver, adrenal-spleen, adrenal-muscle ratios and loss of signal intensity. Specificity varied (60%-93%) but was high for most MRI measures. The performance of PET was similar to MRI for ALR and max SUV measures.

Although more studies had evaluated CT, MRI and PET in the pathway for follow-up of known extra-adrenal malignancy than for incidentally discovered adrenal lesions, estimates of test performance are still based on too small numbers of studies to be able to discern whether any test performs adequately or better than alternative tests from the available data.

4.1.2 Value of an adrenal biopsy (Question 1b)

The following paragraph represents a summary of a recent systematic review carried out with involvement of some of the guideline panel members on published experience with adrenal biopsy and its outcomes (Tamhane, 2016 #248). Inclusion criteria and definition of reference standard differed from the imaging meta-analysis mainly in population selection criteria (as adrenal biopsy is not indicated in incidentaloma population but rather in patients at high risk for malignancy) and in reference standard (where we accepted imaging and clinical follow up
in addition to histopathology as most metastases would not undergo adrenalectomy). We identified 32 studies (Deville, 2002 #13484; Macaskill P, #13485; Moher, 2009 #13486; Silverman, 1993 #237; Puri, 2015 #13487; Martinez, 2014 #13488; Welch, 1994 #240; Rana, 2012 #13489; Mody, 1995 #172; Hussain, 1996 #13490; Wu, 1998 #72; Schwartz, 1998 #73; Porte, 1999 #76; de Agustin, 1999 #67; Lumachi, 2001 #231; Lumachi, 2003 #85; Paulsen, 2004 #230; Kocijancic, 2004 #13493; Lucchi, 2005 #13494; Lumachi, 2007 #95; Quayle, 2007 #236; Tsitouridis, 2008 #142; Osman, 2010 #13496; Mazzaglia, 2009 #13451; Bödtger, 2009 #13497; Eloubeidi, 2010 #13498; Schuurbiers, 2011 #13499; Tyng, 2012 #13500; Tirabassi, 2012 #14; Rana, 2012 #13489; Martinez, 2014 #13390; Puri, 2015 #13487) with a total of 2174 patients which reported at least one outcome of interest (complication rate, non-diagnostic rate, diagnostic accuracy parameters). Of these, only 8 studies (Porte, 1999 #76; Lumachi, 2001 #231; Lumachi, 2003 #85; Lucchi, 2005 #13494; Lumachi, 2007 #95; Quayle, 2007 #236; Tsitouridis, 2008 #142; Tirabassi, 2012 #14) were included for the diagnostic accuracy analysis, reasons for exclusion being lack of any or optimal reference standard for at least 50% patients (n=20) and more than 30% patients with non-adenomas in benign cohort (n=4). Included studies were assessed to be at a moderate risk for bias, most limitations relating to patient selection, assessment of outcome and adequacy of follow up of the study population.

Studies had diverse population inclusion criteria, reference standards and biopsy techniques. Pathology of adrenal lesion was reported only for 1600/2207 cases. Out of these 819 were malignant (703 metastases, 67 ACCs, 49 other malignancies or not specified), 690 were benign and 91 were various other non-malignant lesions (36 pheochromocytomas, 29 granulomas, 16 other). Pooled non-diagnostic rate derived from 30 studies (2030 adrenal biopsy procedures) was 8.6% (CI 6.1%-11%; I² = 84%, p<0.001). Pooled overall complication rate derived from studies (1356 biopsies) was 2.4% (CI 1.5%-3.3%; I² = 21%, p=0.175), though likely under-represented due to differences in both assessment and reporting of complication as well as retrospective nature of the studies. The diagnostic performance of adrenal biopsy was calculated using the data from the 8 studies (323 adrenal biopsy procedures) meeting pre-established eligibility criteria. Performance of adrenal biopsy in the diagnosis of malignancy overall was: sensitivity 87% (CI95% of 78-93%), specificity 100% (CI95% of 76-100%), positive likelihood ratio of 229 (CI95% of 2.9-18145) and negative likelihood ratio of 0.13 (CI95% of 0.07-0.23). Performance was lower (and with even wide 95%CIs) for ACC: sensitivity 70% (CI95% of 42-88%), specificity 98% (CI95% of 86-100%), positive likelihood ratio of 100.43 (CI95% of 8-1245) and negative likelihood ratio of 30.9 (CI95% of 4.16-229).
4.2 Assessment of autonomous cortisol secretion in adrenal incidentalomas

4.2.1 Assessment of autonomous cortisol secretion in relation to clinical outcomes

(Question 2a, Appendices I and II)

Studies were eligible for inclusion independent of the criteria used to define autonomous cortisol secretion. Three different hormonal profiles were distinguished to describe autonomous cortisol secretion associated with adrenal adenomas; Profile 1: serum cortisol > 50 nmol/l (>1.8 µg/dl) after 1-mg, 2-mg, or 8-mg overnight dexamethasone suppression tests, or 2-day low dose dexamethasone test, and one of the following additional endocrine alterations: increased 24-h urinary free cortisol (UFC), low plasma ACTH, elevated midnight serum or salivary cortisol; Profile 2: serum cortisol > 83nmol/l (> 3.0 µg/dl) after 1-mg overnight dexamethasone test and one additional endocrine alteration (same as above); Profile 3: cortisol > 140 nmol/l (> 5 µg/dl) after 1-mg overnight dexamethasone test as sole criterion. The defined profiles do not fit completely with the specific criteria used in all of the studies included. Virtually all diagnostic algorithms are, however, variations of these profiles.

In total, twelve studies were included: seven cross-sectional studies {Chiodini, 2004 #18; Chiodini, 2009 #53; Di Dalmazi, 2012 #12; Eller-Vainicher, 2012 #13; Androulakis, 2014 #17; Olsen, 2012 #15; Vassilatou, 2014 #243} and five cohort studies {Debono, 2014 #19; Di Dalmazi, 2014 #20; Giordano, 2010 #6; Morelli, 2011 #14; Morelli, 2014 #8}. In eight studies, a comparison was made between patients with elevated (group 1) or normal (group 2) cortisol levels after a 1-mg dexamethasone test. Two studies used the biochemical profile 1 and four studies used the biochemical profile 2 with a variation since the post-dexamethasone serum cortisol cutoff was not a mandatory criterion. Three studies identified 3 subgroups of patients {Debono, 2014 #19; Di Dalmazi, 2014 #20; Di Dalmazi, 2012 #12}, normal, intermediate and frankly altered cortisol suppression corresponding to cortisol levels after 1-mg dexamethasone of < 50 nmol/l (< 1.8 µg/dl), between 50 to 140 nmol/l (1.8 µg/dl - 5.0 µg/dl), and > 140 nmol/l (> 5.0 µg/dl), respectively.

In the cross-sectional studies, the risk of bias is estimated as high, given the inability to assess causality and the potential for residual confounding factors, and these issues hamper the ability to make firm conclusions from these studies. Differences in diagnostic protocols, definitions of outcome, and duration of follow-up were associated with considerable heterogeneity between and within studies.

**Outcome measures**

*Change in biochemical profile*
In three studies with a median follow-up of 3, 6.9, and 7.5 years no patient progressed to overt Cushing’s syndrome during follow-up {Di Dalmazi, 2014 #20; Giordano, 2010 #6; Morelli, 2014 #8}.

Change in metabolic and cardiovascular profile

The risk of type 2 diabetes was higher in patients with impaired cortisol suppression after 1-mg dexamethasone test and increased further during follow-up {Di Dalmazi, 2014 #20; Di Dalmazi, 2012 #12; Morelli, 2014 #8}. Also, the risk of hypertension was higher in patients with impaired cortisol suppression and increased further with follow-up {Di Dalmazi, 2012 #12; Morelli, 2014 #8; Olsen, 2012 #15; Vassilatou, 2009 #10}. A smaller study did not confirm the increase in diabetes and hypertension with time {Giordano, 2010 #6}.

Major cardiovascular incidents

In two cohort studies {Di Dalmazi, 2014 #20; Morelli, 2014 #8}, the incidence of cardiovascular events was higher in patients with altered cortisol suppression.

Mortality

Two studies reported on mortality {Debono, 2014 #19; Di Dalmazi, 2014 #20} and found an increased mortality risk in patients with higher cortisol levels after 1-mg dexamethasone. However, the results were adjusted for other prognostic factors only in the first study, and effect estimates were uncertain due to low number of events.

Risk of vertebral fractures

Four studies reported a higher prevalence of vertebral fractures {Chiodini, 2004 #18; Chiodini, 2009 #53; Di Dalmazi, 2012 #12; Eller-Vainicher, 2012 #13} in patients with impaired cortisol suppression. In a cohort study {Morelli, 2011 #14}, the incidence of new vertebral fractures was higher in patients with impaired cortisol suppression. However, most of the detected vertebral fractures were minor and of uncertain clinical impact.

4.2.2. Surgery vs. conservative management in patients with autonomous cortisol secretion (Question 2b, Appendices III and IV)

For question 2b, four studies were included in which surgery was compared to a conservative approach: one randomized controlled trial and three observational studies. The randomized trial {Toniato, 2009 #22} reported on patients with autonomous cortisol secretion who underwent surgery (n=23) or were treated by a conservative approach (n=22). The
mean follow up was 7.7 years and the results were only a qualitative description of changes in hypertension, diabetes mellitus or dyslipidemia.

Tsuiki et al. included patients with autonomous cortisol secretion and compared a group treated by surgery (n=10) and a group treated conservatively (n=10) \{Tsuiki, 2008 \#23\}. Follow up was 7-19 months. The second cohort study included 41 patients with autonomous cortisol secretion (25 treated by surgery and 16 conservatively treated) \{Chiodini, 2010 \#11\}. Outcome measures included: proportion of patients with steady, improved, or worsened blood pressure, fasting glucose or LDL cholesterol. In the third study by Iacobone et al, 372 patients with autonomous cortisol secretion (20 treated by surgery and 15 conservatively treated) \{Iacobone, 2012 \#244\}. Outcomes were blood pressure, glucose and cholesterol.

The quality of evidence from these studies is low to very low, mainly due to confounding factors. Only one study was randomized, and none of the studies reported blinded outcome assessment. Most studies were also downgraded for imprecision, due to low number of events. Differences in diagnostic protocols, definitions of outcome, and duration of follow-up were associated with considerable heterogeneity between and within studies.

### Outcome measures

#### Change in metabolic and cardiovascular profile in patients with autonomous cortisol secretion

In the randomized trial, 25% of patients with type 2 diabetes mellitus had normalized glycemic control after surgery \{Toniato, 2009 \#22\}, compared to none in the conservative group. The cohort studies \{Chiodini, 2010 \#11;Tsuiki, 2008 \#23;Iacobone, 2012 \#244\} reported an improvement in glucose levels in 10-48% of patients after surgery. In the conservatively treated groups, none of the patients improved.

The cohort studies \{Chiodini, 2010 \#11;Tsuiki, 2008 \#23;Iacobone, 2012 \#244\} reported an improvement in hypertension and dyslipidemia in some patients after surgery. In the conservatively managed group, none of the patients improved.

#### Risk of vertebral fractures

None of the included studies reported on the risk of vertebral fractures.

#### Major cardiovascular incidents and mortality

None of the included studies reported on the risk of major cardiovascular events or mortality.
4.3 Surgical approach: open vs. minimally-invasive adrenalectomy (Question 3, Appendices V and VI)

As adrenocortical carcinoma is the main threat for an adverse outcome in patients with adrenal incidentaloma undergoing surgery, we focused our efforts with regards to surgery on the management of adrenocortical carcinoma. Nine cohort studies on the surgical treatment of patients with non-metastatic adrenocortical carcinoma were included {Brix, 2010 #24; Cooper, 2013 #25; Donatini, 2014 #26; Fossa, 2013 #27; Lombardi, 2012 #28; Miller, 2010 #29; Miller, 2012 #30; Mir, 2013 #31; Porpiglia, 2010 #32}. Three studies reported on the patients in whom complete resection of the tumor was achieved {Donatini, 2014 #26; Lombardi, 2012 #28; Porpiglia, 2010 #32}.

The quality of evidence from these observational studies is very low, mainly because patient groups were not comparable at baseline with regard to important prognostic characteristics, such tumor stage or size. Tumor stage was, on average, lower in patients with laparoscopic surgery as compared to open surgery. In few studies {Brix, 2010 #24; Mir, 2013 #31}, treatment effects were adjusted for differences in tumor stage. Mostly, however, only uncorrected estimates of recurrence-free and overall survival were reported. Moreover, most studies had imprecise effect estimates.

Outcome measures

Perioperative mortality and morbidity

One study reported on perioperative mortality {Brix, 2010 #24}. In this study, none of the 152 patients died perioperatively. Three studies reported on intraoperative or postoperative complications {Fossa, 2013 #27; Lombardi, 2012 #28; Mir, 2013 #31}. Major postoperative complications (Clavien-classification score 3-5) occurred more often in open surgeries compared to laparoscopic surgeries (RR 1.7, 95% CI 0.5-6.2) but these estimates are imprecise due to low numbers of events.

Completeness of resection

In five studies the completeness of resection was reported {Brix, 2010 #24; Cooper, 2013 #25; Fossa, 2013 #27; Miller, 2010 #29; Mir, 2013 #31}. The pooled estimate of these five studies indicated no clear difference in complete resection between surgical approaches (RR 0.8 (95% CI 0.6 to 1.1)). The results of these studies were inconsistent, leading to much uncertainty regarding this conclusion.

Recurrence-free and overall survival
Eight studies reported on recurrence after surgery, but differed in the presentation of these data. These studies also provided data on overall or disease-specific survival (Brix, 2010 #24; Cooper, 2013 #25; Donatini, 2014 #26; Fossa, 2013 #27; Lombardi, 2012 #28; Miller, 2012 #30; Mir, 2013 #31; Porpiglia, 2010 #32). There is no compelling evidence that one of the approaches (laparoscopic or open adrenalectomy) is superior with regard to time to recurrence and/or survival in patients with adrenocortical carcinoma, provided that rupture of tumor capsule is excluded. However, the studies have significant limitations, inconsistencies and imprecision precluding reliance on this conclusion.

**Pain / patient satisfaction**

None of the studies reported on pain or patient satisfaction.

### 4.4 Natural course of apparently benign adrenal incidentaloma (risk of malignancy or development of hormone excess) (Question 4, Appendix VII and VIII)

A systematic review of fourteen studies assessing the natural course of 1410 patients with apparently benign, non-functioning adrenal incidentalomas (Cawood, 2009 #35) and ten additional cohort studies were included (Chiodini, 2010 #11; Cho, 2013 #3; Comlekci, 2010 #4; Debo no, 2013 #117; Fagour, 2009 #5; Giordano, 2010 #6; Kim, 2005 #7; Morelli, 2011 #14; Morelli, 2014 #8; Muth, 2011 #9; Muth, 2013 #119; Song, 2008 #262; Vassilatou, 2009 #10; Yener, 2009 #121). The systematic review included studies reporting the follow up of adrenal incidentaloma patients, published between 1980 and 2008, including publications that reported more than 20 patients, and in which the majority were referred to an endocrinologist (excluding oncology series). The additional ten studies, published between 2005 and 2014, included 1131 incidentaloma patients with apparently benign non-functioning tumors or with autonomous cortisol secretion.

The quality of evidence from these studies was judged moderate or low. Selection criteria were often not reported, the duration of follow-up was heterogeneous across studies (medians ranging from 19 to 90 months) and the completeness of follow-up was difficult to assess. Information on the protocol of biochemical or radiological re-evaluation was not always provided and standardized. In addition, criteria for hormonal excess were heterogeneous across studies.

**Outcome measures**

**Malignancy**

The estimated pooled risk for developing malignancy in the systematic review was 0.2% (95% CI 0.0 to 0.4) (Cawood, 2009 #35). In two cohort studies, one case of malignancy was
found: one patient with adrenal non-Hodgkin lymphoma and one patient with renal cancer metastasis. In the first case, the imaging characteristics of the adrenal incidentaloma at the first evaluation were not consistent with benign characteristics and the lymphoma may have been misdiagnosed initially {Libe, 2002 #123}. The second case had a history of renal cell carcinoma and it is unclear whether the adrenal mass was found incidentally or during the follow-up for cancer {Tsvetov, 2007 #122}. No case of malignancy was reported in the other 904 patients included in the cohort studies. Importantly, no malignant transformation of a presumably benign incidentaloma was reported.

Development of clinically overt hormone excess

The risk of developing overt Cushing’s syndrome in patients without clinical signs of Cushing’s syndrome at the time of initial assessment ranged in the individual studies from 0% to 4%, whereas the risk of developing autonomous cortisol secretion in the absence of clinically overt Cushing’s syndrome was low, with a pooled estimate from a systematic review of 0.3% {Cawood, 2009 #35}. The risk of developing an aldosterone-producing adenoma in the individual studies ranged from 0% to 2%. The risk of developing a pheochromocytoma ranged from 0% to 2% but it is unclear whether an accurate initial imaging and biochemical screening was performed.
5. Recommendations, Rationale for the Recommendations

5.1. General remarks

The main part of this guideline addresses the management of patients who fulfill the definition of adrenal incidentaloma (section 2.1). In addition, we discuss specific situations separately: bilateral adrenal masses (5.6.1), patients who are young or elderly and frail (5.6.2), and adrenal masses detected during evaluation for extra-adrenal malignancy (5.6.3).

R.1.1 We recommend that patients with adrenal incidentalomas are discussed in a multidisciplinary expert team meeting, if at least one of the following criteria is met (Figure 1):

- Imaging is not consistent with a benign lesion.
- There is evidence of hormone excess (including ‘autonomous cortisol secretion’).
- Evidence of significant tumor growth during follow-up imaging.
- Adrenal surgery is considered.

Reasoning:

Although we believe that the ideal would be for all patients with adrenal incidentalomas to be managed by an expert multidisciplinary team, in many health care settings this is an unrealistic aspiration. Despite lack of compelling evidence, we aimed at identifying subgroups of patients that would be most likely to benefit from multidisciplinary team discussion, and that these discussions occur quickly for patients that meet the criteria above. The core multidisciplinary team should consist of at least a radiologist, an endocrinologist, and a surgeon, all with significant experience in adrenal tumors. Furthermore, this team should have access to anesthetists and an endocrine pathologist, who are experienced in adrenal tumors. Although it is beyond the scope of this guideline, the use of a standardized pathology report is highly recommended.

There is sufficient evidence that higher surgical volume correlates with better outcome, however, for the time being no specific numbers of operations per year that result in this favorable outcome can be recommended {Park, 2009 #50; Kerkhofs, 2013 #51; Lombardi, 2012 #52; Cooper, 2013 #25}. 
Figure 1: Flow-chart on the management of patients with adrenal incidentalomas (overview)

Adrenal incidentaloma¹

Assess in parallel

Potentially malignant?
- Non-contrast CT
- if uncertain: consider FDG-PET, MRI with chemical shift, washout CT

Functionally active?
- Clinical assessment
- 1mg dexamethasone test
- Plasma or urinary metanephrines
- Aldosterone/renin ratio²
- Sex-hormones and steroid precursors³

Aim at the establishment of a definitive diagnosis

Discuss in multidisciplinary team:

Non-functioning, benign lesion e.g. adenoma, lipoma
- No further investigations

Adrenal adenoma with autonomous cortisol secretion
- See Figure 2

Clinically relevant hormone excess or malignant tumor e.g. pheochromocytoma, Conn, Cushing, ACC
- Surgery, details see Figure 3

Indeterminate mass
- Consider additional investigations, surgery or follow-up

¹ For patients with history of extra-adrenal malignancy, see special section 5.6.4
² only in patients with concomitant hypertension and/or hypokalemia
³ only in patients with clinical or imaging features suggestive of adrenocortical carcinoma
5.2. Assessment of the risk of malignancy

R.2.1 We recommend aiming to establish if an adrenal mass is benign or malignant at the time of initial detection.

Reasoning

It is critical to know if an adrenal mass is malignant or benign as clinical management is dependent on establishing this fact, regardless of whether the mass is functioning or not. Malignant lesions may need urgent surgical intervention and other therapies, and delay may cause harm.

R.2.2 We recommend that all adrenal incidentalomas undergo an imaging procedure to determine if the mass is homogeneous and lipid-rich and therefore benign (XOOO). For this purpose, we primarily recommend the use of non-contrast CT (XOOO).

R.2.3 We suggest that if the non-contrast CT is consistent with a benign adrenal mass (Hounsfield units ≤ 10) that is homogeneous and smaller than 4 cm no further imaging is required (XOOO).

Reasoning

In patients with no known extra-adrenal malignancy adrenal incidentalomas are likely to be benign. The non-contrast CT value is reflective of tissue density. Benign lesions including lipid rich adenoma, myelolipoma, fluid-filled homogenous cysts, and other soft tissue tumors (ganglioneuromas, some schwannomas) have low CT density ≤ 10 HU. Based on the systematic review and meta-analysis {Dinnes, 2016 #246}, in patients presenting without known malignancy a non-contrast CT with HU of ≤10 was only found in those with benign disease, whereas in patients with extra-adrenal malignancy 7% of cases with non-contrast HU ≤10 turned out to be malignant.

Similar to CT, the results of MRI with chemical shift imaging are based on the lipid content of masses {Rodacki, 2014 #268;Seo, 2014 #269}. Unlike CT (or FDG-PET) MRI has the advantage of avoiding ionizing radiation and its attendant risks to the patient. However, the quantitative assessment of loss in signal intensity is not well standardized between the different studies and, therefore, evidence base for performance of MRI in the diagnosis of malignancy is insufficient to make strong recommendations. Moreover, the interpretation of the images might be more dependent on the experience of the radiologist than for CT assessment. In addition, the meta-analysis was not able to determine the diagnostic value of MRI due to the low number and quality of eligible studies.
In conclusion, the panel felt - despite the limited evidence - confident about the negative predictive value of non-contrast CT to recommend that additional imaging was not necessary when benign characteristics were found in an adrenal mass < 4 cm, especially as additional imaging may also risk false positive results and significant psychological and financial burden for patients and the health system, respectively. We acknowledge that the cutoff of 4 cm is not based on good evidence from clinical studies, but the panel felt it is necessary to provide clear guidance based on clinical experience.

MRI with chemical shift has an even poorer evidence base with regard to its diagnostic value in excluding malignancy and therefore should be first choice only where a CT is less desirable (e.g. pregnancy, children). However, if an MRI with chemical shift is already performed and the results are unambiguous, a multidisciplinary expert team might judge this as sufficient for an individual patient.

R.2.4 If the adrenal mass is indeterminate on non-contrast CT and the results of the hormonal work-up do not indicate significant hormone excess, there are three options that should be considered by a multidisciplinary team acknowledging the patient’s clinical context: immediate additional imaging with another modality, interval imaging in 6 to 12 months (non-contrast CT or MRI), or surgery without further delay.

Reasoning
Evidence of targeted evaluation for “second or third-line” imaging in patients with indeterminate adrenal mass is very poor (see section 4.1 and {Dinnes, 2016 #246} for details). However, the panel considered it important to provide some guidance for daily clinical practice (Table 4), although consensus was not reached other than agreeing that such discussions needed to be individualized and should take place within a multidisciplinary team meeting.

The advantages and limitations of MRI with chemical shift are already discussed at R 2.3. Contrast washout CT has very limited and low quality evidence from studies {Dinnes, 2016 #246}. CT washout is widely available but there is huge variability in the protocols applied and therefore poor comparability between studies and centers; in addition, the meta-analysis could only identify a single eligible study reporting CT washout study results, carried out in patients without a history of extra-adrenal malignancy.

FDG-PET/CT has the advantage that the risk of false negative results (namely missing a malignant adrenal tumor) is quite low, and this refers mainly to a few subtypes of extra-adrenal malignancies with low uptake {Karam, 2006 #207;Tsukamoto, 2007
This procedure is, however, more expensive, not always easily available, and has the disadvantage that several benign adrenal tumors (e.g. functional adenomas or benign pheochromocytoma) may be FDG-positive {Timmers, 2009 #209;Alencar, 2011 #212}.

Table 4: Imaging criteria suggesting a benign adrenal mass¹

<table>
<thead>
<tr>
<th>Non-contrast CT</th>
<th>≤ 10 HU</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRI - chemical shift²</td>
<td>Loss of signal intensity on out-phase imaging consistent with lipid-rich adenoma</td>
</tr>
<tr>
<td>CT with delayed contrast media washout²,³</td>
<td>Absolute washout &gt; 60%</td>
</tr>
<tr>
<td>¹⁸F-FDG-PET²</td>
<td>Relative washout &gt; 40%</td>
</tr>
<tr>
<td></td>
<td>Absence of FDG uptake or uptake less than the liver⁴</td>
</tr>
</tbody>
</table>

¹ These criteria apply only for masses with homogenous appearance, or masses that have other clear characteristics consistent with benign disease, e.g. myelolipoma. A homogeneous mass is defined as a lesion with uniform density or signal intensity throughout. The measurements/region of interest (ROI) should include at least 75% of a lesion without contamination by tissues outside the adrenal lesion. Inhomogeneous lesions should not be subjected to MRI or washout CT for further characterization.

² Evidence is weak for MRI, CT with contrast washout, and FDG-PET and no comparative studies on "second line imaging" are available. Thus, in this guideline we clearly recommend non-contrast CT as imaging procedure of choice.

³ There is no clear evidence about the best time interval. We recommend 10 or 15 min.

⁴ Certain metastasis (e.g. from kidney cancer or low grade lymphoma) may be FDG negative.

Whilst the panel was in favor of attempts to fully characterize the adrenal mass on imaging, due to the limitations summarized above, it considered that in patients with indeterminate results on non-contrast CT further imaging by one of the modalities detailed above should be arranged. Due to the lack of evidence and studies reporting direct comparison the panel was not able to clearly judge one method over another. Alternatively, in patients without a strong suspicion of malignancy and older patients, follow-up imaging 6-12 months after the initial scan could be undertaken. The rationale for a follow-up scan at 6-12 months is based on the principle that either primary adrenal malignancies or adrenal metastases are likely to increase in size over this time period; lack of growth may be taken as an indicator of benign disease in radiologically indeterminate lesions. The exact timing of this imaging should be individualized. However, especially in cases with a low likelihood of a malignant tumor the panel favors a time interval of 12 months. There are no published size or volume cut-offs commonly agreed or with evidence base to support that they indicate growth suggestive of malignancy; the expert panel agreed that an increase in > 20% of the largest tumor diameter together with an at least 5 mm increase in this diameter should be considered as suspicious.
R.2.5 We recommend against the use of an adrenal biopsy in the diagnostic work-up of patients with adrenal masses unless there is a history of extra-adrenal malignancy (see R6.3.5).

Reasoning
Adrenal biopsy has a limited role in evaluation of adrenal masses – mainly in diagnosis of extra/adrenal malignancy, lymphoma, infiltrative or infectious process. Even in such situations, adrenal biopsy should only be performed by an experienced radiologist and when it is required to guide further care. We particularly recommend against an adrenal biopsy if an adrenal mass is likely to be an adrenocortical carcinoma, because a biopsy of such a tumor runs the risk of tumor dissemination precluding an R0 resection (although this risk seems to be low {Williams, 2014 #152}). The only exception might be if a formal confirmation of the diagnosis is needed in an inoperable tumor to inform oncological management or as part of a clinical trial.
5.3. Assessment for hormone excess

R.3.1 We recommend that every patient with an adrenal incidentaloma should undergo careful assessment including clinical examination for symptoms and signs of adrenal hormone excess.

Reasoning
All patients should undergo a careful evaluation with detailed history and physical examination since a second round evaluation may detect clues of overt hormone excess that were overlooked initially. For the clinical assessment and subsequent diagnostic procedures for Cushing’s syndrome, primary aldosteronism, and pheochromocytoma, we refer to guidelines of other societies {Nieman, 2008 #47; Lenders, 2014 #48; Funder, 2008 #276}. Rapidly developing hirsutism or virilization is a clinical indicator for an androgen-producing tumor, and should be addressed by measuring testosterone and androgen precursors, whereas recent onset of gynecomastia should trigger measurement of estradiol {Fassnacht, 2009 #149; Fassnacht, 2004 #148; Libe, 2007 #157; Else, 2014 #153} (see also R.3.10).

R.3.2 We recommend that all patients with adrenal incidentalomas undergo a 1-mg overnight dexamethasone suppression test to exclude cortisol excess (XXOO).

R.3.3 We suggest interpretation of the results of the 1-mg overnight dexamethasone test as a continuous rather than categorical (yes/no) variable (XOOO). However, we recommend using serum cortisol levels post dexamethasone ≤ 50 nmol/l (≤ 1.8 µg/dl) as a diagnostic criterion for the exclusion of autonomous cortisol secretion (XXOO).

R.3.4 We suggest that post dexamethasone serum cortisol levels between 51 and 140 nmol/l (1.9 - 5.0 µg/dl) should be considered as evidence of ‘possible autonomous cortisol secretion’ and cortisol levels post dexamethasone > 140 nmol/l (> 5.0 µg/dl) should be taken as evidence of ‘autonomous cortisol secretion’. Additional biochemical tests to confirm cortisol secretory autonomy and assess the degree of cortisol secretion might be required (Figure 2). However, for the clinical management the presence of potentially cortisol-related comorbidities (Table 2) and age of the patient are of major importance (Figure 2).
Reasoning

A variety of diagnostic algorithms have been used to exclude cortisol excess or to define so-called ‘subclinical hypercortisolism’, but in the literature there are no head to head comparisons between tests to assess their diagnostic performance (see section 4.2.1). However, the panel recommends the use of the 1-mg overnight dexamethasone test based on pathophysiological reasoning, simplicity, and the fact that the test was incorporated in the diagnostic algorithms of most studies. It is important to consider drugs or conditions that interfere with this test (see Appendix Table A3). In published guidelines and reviews variable thresholds have been recommended (Grumbach, 2003 #39;Young, 2007 #43;Terzolo, 2011 #33;Tabarin, 2008 #59). Several studies have used post dexamethasone serum cortisol values between 50 and 140 nmol/l (1.8 - 5.0 µg/dl) and/or required further tests to secure the diagnosis of ‘autonomous cortisol secretion’. However, in none of these additional tests was the performance convincing enough to ultimately establish diagnostic criteria.

The panel appreciated that this ongoing debate reflects a biological continuum with no clear separation between non-functioning adenomas and functioning adenomas associated with some degree of cortisol excess. However, a value of ≤ 50 nmol/l (≤ 1.8 µg/dl) may be regarded as normal, excluding cortisol excess. This cut-off is supported by studies demonstrating that patients with post dexamethasone cortisol values > 50 nmol/l (> 1.8 µg/dl) have an increased morbidity or mortality (Debono, 2014 #19;Di Dalmazi, 2014 #20). Since the probability of clinically relevant cortisol excess increases the higher the post-dexamethasone serum cortisol value and that the principle of dexamethasone testing is based on pharmacological suppression of ACTH secretion, we propose the following terminology be used on biochemical grounds. For patients without overt Cushing’s syndrome and a serum cortisol post dexamethasone between 51 and 140 nmol/l we propose the term ‘possible autonomous cortisol secretion’ and for higher values the term “autonomous cortisol secretion”. However, for the clinical management, the presence of potentially related comorbidities (Table 2) and age of the patient are of major relevance (Figure 2).

The majority of panel members (but not all) preferred additional biochemical tests to confirm cortisol secretory autonomy and assess the degree of cortisol secretion. However, we acknowledge that use of several tests may be associated with an increased likelihood of at least one being a false positive result. Nevertheless, we suggest measurement of basal morning plasma ACTH and to repeat the dexamethasone test after 3-12 months in all patients with ‘possible autonomous cortisol secretion’ and comorbidities. In patients with ‘autonomous cortisol secretion’ we suggest the additional measurement of 24-h urinary free cortisol and/or late-night salivary cortisol (although few studies suggest a poor performance of this parameter in patients with incidentaloma). Following the concept that cortisol secretion in patients with ‘autonomous cortisol secretion’ is independent of ACTH, a higher dose of
Dexamethasone (e.g., 3mg, 2×2mg, or 8mg) might also be reasonable as additional test. However, the published literature is too limited and controversial to make a clear statement on these tests.

**Figure 2: Assessment and management of ‘autonomous cortisol secretion’ in patients with adrenal incidentalomas**

- The majority of but not all panel members preferred additional biochemical tests to better judge the degree of cortisol secretion. In patients with comorbidities, we suggest to measure plasma ACTH and to repeat the dexamethasone test in 3-12 months.
- We suggest additional biochemical tests to better judge the degree of cortisol secretion: plasma ACTH, 24-h urinary free cortisol, (and/or late-night salivary cortisol), and repetition of the dexamethasone test in 3-12 months.
- See Table 2 for potentially cortisol-related comorbidities.
- Choice for surgery should always be individualized.
- Need of follow-up by an endocrinologist

**R.3.5 We recommend against considering ‘autonomous cortisol secretion’ as a condition with a high risk for the development of overt Cushing’s syndrome (XXOO).**

**Reasoning**

Studies reporting on follow-up of patients with adrenal incidentalomas have uniformly found a very low percentage (< 1%) of patients with ‘autonomous cortisol secretion’ progressing to overt Cushing’s syndrome (Cawood, 2009 #35; Barzon, 1999 #112; Barzon, 2003 #38; Bernini, 2005 #137; Fagour, 2009 #136; Libe, 2002 #123; Terzolo, 2005 #135; Terzolo, 1998 #134; Nieman, 2015 #142).
R.3.6 We recommend screening patients with ‘possible autonomous cortisol secretion’ or ‘autonomous cortisol secretion’ for hypertension and type 2 diabetes mellitus (XOOO) and suggest offering appropriate treatment of these conditions.

Reasoning

Studies from different research groups have consistently demonstrated an association between cortisol excess and hypertension and hyperglycemia (Terzolo, 2005 #146; Terzolo, 2005 #135; Tauchmanova, 2002 #143; Emral, 2003 #144; Reincke, 1996 #166; Bernini, 2003 #164; Di Dalmazi, 2012 #12; Fernandez-Real, 1998 #165; Morelli, 2010 #163; Rossi, 2000 #162). The association with dyslipidemia is less proven, although biologically plausible. There is also evidence that patients with cortisol excess are at increased risk of cardiovascular events and excess mortality (Debono, 2014 #19; Di Dalmazi, 2014 #20).

Therefore, the panel recommended screening for these conditions, which are well known independent cardiovascular risk factors and which may be driven by cortisol excess, and to treat them according to current guidelines.

R.3.7 We suggest screening patients with ‘autonomous cortisol secretion’ for asymptomatic vertebral fractures (XOOO) and to consider appropriate treatment of these conditions (XOOO).

Reasoning

Several studies, although mainly from a single research group, have demonstrated an association between autonomous cortisol secretion and an increased risk of vertebral fractures (Hadjidakis, 2003 #145; Chiodini, 2004 #18; Chiodini, 2009 #53; Chiodini, 2010 #11; Eller-Vainicher, 2012 #13; Morelli, 2011 #14). Although most of the fractures are asymptomatic, the panel suggests screening patients with ‘autonomous cortisol secretion’ for vertebral fractures at least once at the time of diagnosis. This may be done by re-evaluating the available images (if a CT was performed) or by plain X-ray. The panel did not reach consensus on recommending assessment of bone mineral density by dual-energy x-ray absorptiometry (DXA). If osteoporosis is present, active treatment should be considered. If there is no other likely explanation for the osteoporosis, removal of the adrenal adenoma might be considered (see R3.8).
R.3.8 We suggest an individualized approach in patients with ‘autonomous cortisol secretion’ due to a benign adrenal adenoma and comorbidities potentially related to cortisol excess for adrenal surgery (XOOO). Age, degree of cortisol excess, general health, comorbidities and patient's preference should be taken into account. In all patients considered for surgery, ACTH-independency of cortisol excess should be confirmed.

Reasoning

Due to the limitations of current literature, especially the lack of high-quality randomized trials, the panel could not reach consensus on the exact indication for surgery for ‘autonomous cortisol secretion’. The panel appreciated that there is some evidence of improvement of hypertension, hyperglycemia and dyslipidemia with surgery but this is based on low quality data. However, no data are available on clinically relevant endpoints (e.g. mortality or major cardiovascular events). Thus, the decision to undertake surgery should be individualized taking into account factors that are linked to surgical outcome, such as patient’s age, duration and evolution of comorbidities and their degree of control, and presence and extent of end organ damage. Because it is not possible to be sure that surgical intervention will normalize or improve the clinical phenotype of an individual patient, there was no complete agreement within the panel with regard to the optimal management of these patients. Approaches varied between two ends of the spectrum. Overall, the group agreed that there is an indication of surgery in a patient with post dexamethasone cortisol > 140 nmol/l (> 5 µg/dl) and the presence of at least two comorbidities potentially related to cortisol excess (e.g. type 2 diabetes, hypertension, obesity, osteoporosis), of which at least one is poorly controlled by medical measures. Conversely, there is no reason for surgery, when serum cortisol post dexamethasone is < 140 nmol/l (< 5 µg/dl) and no comorbidities are present. However, some panel members favor a more proactive approach, for example considering surgical intervention, especially in younger patients with ‘possible autonomous cortisol’ secretion and less comorbidities potentially related to cortisol excess, even if controlled by medical therapy.

However, there was consensus that when surgery is considered due to ‘autonomous cortisol secretion’, ACTH-independency has to be proven by a suppressed or low basal morning plasma ACTH. If not, other reasons of cortisol excess have to be considered.

R.3.9 We recommend excluding pheochromocytoma by measurement of plasma free metanephrines or urinary fractionated metanephrines.
Reasoning:
For details we refer to the most recent guidelines of other societies (e.g. {Lenders, 2014 #48}). Of note, there are clinically silent pheochromocytomas {Haissaguerre, 2013 #150;Erickson, 2001 #241;Kopetschke, 2009 #242} that might lead to hemodynamic instability during surgical excision {Lafont, 2015 #151}. Thus, metanephrines should be measured in normotensive patients and the diagnosis of pheochromocytoma should be considered in patients with borderline values of metanephrines and indeterminate imaging features on CT. In adrenal lesions with imaging criteria of an adenoma the likelihood of a pheochromocytoma is extremely low {Sane, 2012 #210;Schalin-Jantti, 2015 #217}. Thus, it seems to be reasonable to avoid measuring metanephrines in patients with clear evidence of an adrenal adenoma, but definitive data in this area are lacking.

R.3.10 In patients with concomitant hypertension or unexplained hypokalemia, we recommend the use of the aldosterone / renin ratio to exclude primary aldosteronism.

Reasoning:
For details we refer to the most recent guidelines of other societies (e.g. {Funder, 2008 #276}).

R.3.11 We suggest measurement of sex hormones and steroid precursors in patients with imaging or clinical features suggestive of adrenocortical carcinoma.

Reasoning:
Adrenocortical carcinoma is associated in more than half of cases with elevated sex hormones and steroid precursors {Berruti, 2012 #156;Fassnacht, 2013 #54;Libe, 2007 #157;Else, 2014 #153}. The panel does not recommend measurement of these hormones in patients with adrenal incidentalomas on a routine basis, but in cases with indeterminate adrenal mass by imaging or clinical signs for androgen excess, significantly increased sex hormones or precursors might clearly point towards adrenocortical carcinoma. Thus, measurement of serum DHEA-S, androstenedione, 17-hydroxyprogesterone as well as testosterone in women and estradiol in men and postmenopausal women can prove the adrenocortical nature of the adrenal mass. However, the panel acknowledges that the published evidence for this suggestion is very low {Arlt, 2011 #34;Fassnacht, 2013 #54}. A
very promising new tool to discriminate benign from malignant adrenocortical tumors appears the analysis of a comprehensive urinary steroid profile measured by GC-MS or LC-MS (Arlt, 2011; Kerkhofs, 2015).
5.4. Surgical treatment

R.4.1 We recommend adrenalectomy as the standard of care for unilateral adrenal tumors with clinically significant hormone excess.

Reasoning:
As covered by several other guidelines, there is consensus that adrenal tumors leading to clinically significant hormone excess (e.g. primary aldosteronism, Cushing syndrome or pheochromocytoma) should be surgically removed {Lenders, 2014 #48;Funder, 2008 #276;Nieman, 2015 #138}. The guideline group is convinced that for these tumors the same rules regarding the surgical approach should apply as for endocrine inactive tumors (see below). There are no substantiated reasons why the surgical approach for hormone-producing tumors should differ from that in endocrine inactive tumors (R4.3-5).

R.4.2 We recommend against performing surgery in patients with an asymptomatic, non-functioning unilateral adrenal mass and obvious benign features on imaging studies (XOOO).

Reasoning:
Most adrenal incidentalomas are non-functioning benign lesions (e.g. adenomas, myelolipomas) that do not cause harm. Therefore, there is broad consensus that the majority of these adrenal masses do not require surgery. The guideline group defined two criteria that need to be fulfilled to allow characterization of a unilateral adrenal lesion as not harmful: (i) imaging criteria indicating a benign lesion (see section 5.2, Table 4) (ii) no relevant endocrine activity (see section 5.3).

There was considerable discussion by the group if a certain cutoff of size should be a factor to consider surgery. There was consensus that a tumor with a diameter of ≤ 4 cm with benign imaging features does not require surgery, accepting that this size cutoff is arbitrary. However, due to the paucity of follow-up data on the natural history of large apparently benign adrenal incidentalomas the panel was divided on the approach to the management of patients with larger lesions. One approach is to rely on imaging criteria only to determine if a lesion is benign irrespective of size. Alternatively, because of clinician or patient uncertainty about the increasing incidence of malignancy the larger is size, surgery may be considered in larger lesions (e.g. > 4 cm) even if imaging characteristics suggest a benign nature of the mass, allowing for an individualized approach. We voted against a certain cutoff which indicates that surgery has to be performed. However, we acknowledge that with a larger
tumor size patients and clinicians might feel increasingly uncomfortable, but again an
dividualized approach was deemed most appropriate.

R.4.3 We suggest performing laparoscopic adrenalectomy in patients with unilateral
adrenal masses with radiological findings suspicious of malignancy and a
diameter ≤ 6 cm, but without evidence of local invasion (XOOO).

R.4.4 We recommend performing open adrenalectomy for unilateral adrenal masses
with radiological findings suspicious of malignancy and signs of local invasion
(XOOO).

R.4.5 We suggest an individualized approach in patients that do not fall in one of the
above mentioned categories (XOOO).

Reasoning:
The main threat of a unilateral adrenal mass, which is suspected to be malignant, is
adrenocortical carcinoma. For adrenocortical carcinoma without metastases, surgery is the
most important single therapeutic measure. Thus, the high expertise of the surgeon is of
major importance. Although we cannot provide a specific number of required operations per
year, we have no doubts that surgical volume correlates with better outcome. As summarized
above (section 4.1.3) there are nine cohort studies on surgery for localized adrenocortical
carcinoma comparing laparoscopic versus open adrenalectomy, each with more than ten
patients per group {Brix, 2010 #24; Cooper, 2013 #25; Donatini, 2014 #26; Fossa, 2013
#27; Lombardi, 2012 #28; Miller, 2010 #29; Miller, 2012 #30; Mir, 2013 #31; Porpiglia, 2010
#32}, but these studies are, however, hampered by methodological flaws, and importantly
none was randomized. Nevertheless, based on these data and the clinical experience of the
guideline group members, it was judged that laparoscopic adrenalectomy may be justified for
tumors with radiological signs of malignancy but only where there was no evidence of local
invasion. For this approach the group arbitrarily chose a cut-off size for the adrenal tumor of
≤ 6 cm, because for this size it is believed that laparoscopic adrenalectomy is feasible
without rupture of tumor capsule (a major risk factor for recurrence), and is beneficial for the
patient (e.g. less pain, shorter hospital stay). However, with increasing tumor size risk of
tumor capsule rupture may increase. If during surgery there is a risk of tumor capsule
rupture, conversion to open procedure should be performed. We acknowledge that the cutoff
of 6 cm for laparoscopic vs. open adrenalectomy is not based on good evidence from clinical
studies, and we recognize that laparoscopic adrenalectomy for tumors < 6 cm is common
practice in most centers. However, this cutoff by no means indicates that every tumor smaller
than 6 cm has to undergo laparoscopic adrenalectomy and every tumor larger than 6 cm
open adrenalectomy. We are convinced that in many cases an individualized decision process is required to find the best surgical approach for a given patient. This is also true for all patients that do not fall in one of the categories described in R.4.2 - 4.4.

There are no sufficiently powered studies published on the approach to patients with stage III adrenocortical carcinoma (local invasion, lymph nodes metastases, or tumor thrombus in the renal vein or vena cava). However, the guideline group unanimously voted for open adrenalectomy as standard procedure for this stage of disease.

R.4.6 We recommend perioperative glucocorticoid treatment at major surgical stress doses, as recommended by guidelines, in all patients undergoing surgery for an adrenal tumor where there is evidence of ‘possible autonomous cortisol secretion’ or ‘autonomous cortisol secretion’.

Reasoning:
Autonomous cortisol secretion may lead to adrenal insufficiency after removal of the adrenal source of cortisol (even in patients with incompletely suppressed ACTH {Eller-Vainicher, 2010 #214}). Therefore, the group unanimously recommends intra- and post-operative glucocorticoid replacement, preferably by hydrocortisone in patients with an adrenal tumor and evidence for ‘(possible) autonomous cortisol secretion’ (post dexamethasone cortisol > 50 nmol/l (> 1.8 µg/dl)) even if there are no clinical sign of cortisol excess. This should follow the suggestions for major stress dose replacement as per a recent international guideline {Bornstein, 2016 #211}. Postoperatively, the glucocorticoid dose should be tapered individually by a physician experienced in this clinical scenario.
‘autonomous cortisol secretion’ is not automatically judged as clinically relevant (see section 5.3 for details).

In tumors with benign radiological features and a tumor size > 4 cm, surgery might also be individually considered (see text).
5.5 Follow-up of patients not undergoing adrenal surgery after initial assessment

R.5.1 We suggest against further imaging during follow-up in patients with an adrenal mass < 4cm with clear benign features on imaging studies (XOOO).

Reasoning
Amongst more than 2300 patients included in published follow-up studies {Cawood, 2009 #35;Terzolo, 2011 #33} there is no report of occurrence of adrenal malignancy in adrenal incidentalomas displaying typical features of adrenocortical adenomas at initial imaging studies. Therefore, the panel does not support repeating imaging investigations if the initial work-up is unequivocally consistent with a benign lesion. However, many patients with adrenal incidentalomas > 4 cm in diameter have undergone adrenalectomy in the past and the literature on follow-up of non-operated large adrenal incidentalomas is scarce. Thus, and similar to the discussion on the surgical treatment (R.4.2), some panel members argued that one follow-up imaging (non-contrast CT or MRI) after 6-12 months might be considered in lesions > 4 cm.

R.5.2 In patients with an indeterminate adrenal mass (by imaging), opting not to undergo adrenalectomy following initial assessment, we suggest a repeat non-contrast CT or MRI after 6-12 months to exclude significant growth (XOOO). We suggest surgical resection if the lesion enlarges by more than 20% (in addition to at least a 5 mm increase in maximum diameter) during this period. If there is growth of the lesion below this threshold, additional imaging again after 6-12 months might be performed.

Reasoning
Contrary to benign adrenal tumors that may exhibit a slow growth tendency with time, malignant adrenal lesions (mostly adrenocortical carcinoma and metastases) are almost invariably characterized by a rapid growth within months {Else, 2014 #153;Fassnacht, 2013 #54;Berruti, 2012 #156}. Consequently, the panel recommends performing follow-up imaging studies in adrenal incidentaloma, in which the benign nature cannot be established with certainty at initial evaluation, in order to recognize early a rapidly growing mass. Many clinicians would opt for surgical removal if the mass is of larger size and cannot be determined as benign with certainty.
Lack of growth of an adrenal mass over a period of 6-12 months makes a malignant mass highly unlikely while surgery is recommended if significant rapid growth is observed. There is no generally accepted definition of significant growth of an adrenal tumor. However, the panel proposes an adaptation of the RECIST 1.1 criteria (Eisenhauer, 2009 #56). These criteria, which are used in most oncological trials, define progress by an increase of 20% of the largest diameter. Although RECIST 1.1 criteria are not validated for the differentiation between benign and malignant adrenal tumors, the 20% cut-off together with an absolute increase of at least 5 mm in diameter may serve as warning for significant growth and reconsideration then given for surgical excision.

The panel is aware that there are exceptional cases of malignant adrenal tumor without significant growth for several years (Nogueira, 2015 #55; Ozsari, 2015 #158). However, this can be considered a very rare exception and does not justify following all patients with an adrenal mass with repeated imaging over years. However, in case there is some measurable growth (10-20%) that does not qualify for the above-mentioned criteria, additional follow-up imaging should be considered.

R.5.3 We suggest against repeated hormonal work-up in patients with a normal hormonal work-up at initial evaluation unless new clinical signs of endocrine activity appear or there is worsening of comorbidities (e.g. hypertension and type 2 diabetes) (XOOO).

Reasoning

The pooled risk of developing clinically relevant hormonal excess (e.g. primary aldosteronism, Cushing's syndrome and pheochromocytoma) is below 0.3% in patients with initial hormonal work-up consistent with a non-functioning lesion (Cawood, 2009 #35; Terzolo, 2011 #33).

Development of 'autonomous cortisol secretion' without signs of overt Cushing's syndrome is the most frequently reported event during the follow-up and may occur in 8 to 14% of patients with non-functioning adrenal incidentalomas. Owing to the risk of false positive results (Elamin, 2008 #159) the panel does not recommend systematic follow-up hormonal investigations in patients with non-functioning adrenal incidentalomas at initial evaluation (i.e cortisol ≤ 50 nmol/l (≤ 1.8 µg/dl) post 1-mg overnight dexamethasone test).

R.5.4 In patients with 'autonomous cortisol secretion' without signs of overt Cushing's syndrome (see Figure 2), we suggest annual follow-up with re-
assessment for cortisol excess and careful assessment of comorbidities potentially related to cortisol excess (XOOO). Based on the outcome of this evaluation the potential benefit of surgery should be considered.

Reasoning

As discussed above, it is extremely rare that patients will develop overt Cushing’s syndrome during follow-up. However, as elaborated in section 5.3, the panel considers ‘autonomous cortisol secretion’ as a condition associated with several comorbidities (Table 2). Therefore, the panel recommends annual clinical follow-up in patients with ‘autonomous cortisol secretion’ and in patients with both ‘possible autonomous cortisol secretion’ and potentially associated comorbidities, in whom an initial decision against surgery was made (Figure 2). Clinical follow-up should include evaluation of potentially cortisol excess-related comorbidities. The presence or worsening of these conditions should prompt hormonal re-evaluation at any time during follow-up. Appropriate symptomatic treatment and reconsideration of surgical removal of the adrenal mass is recommended, in line with the observed changes in the clinical and hormonal status of the patient.

In the absence of evidence, we suggest that follow-up by an endocrinologist beyond 2-4 years is not needed in patients with no relevant change during this time.
5.6. Special circumstances

5.6.1 Patients with bilateral adrenal incidentalomas

R.6.1.1 We recommend that for patients with bilateral adrenal masses each adrenal lesion is assessed at the time of initial detection according to the same imaging protocol as for unilateral adrenal masses to establish if either or both lesions are benign or malignant.

Reasoning:
In most cases bilateral adrenal masses represent benign bilateral adrenocortical disease: either bilateral adenomas, macronodular hyperplasia, or distinct bilateral nodules with normal or atrophic cortex intervening. The possibility of metastases (especially in patients with known malignancy), adrenal lymphoma or bilateral pheochromocytomas should also be considered. Moreover, bilateral adrenal masses may represent co-occurrence of different entities, such as adenoma, pheochromocytoma, cyst, myelolipoma, adrenocortical carcinoma, etc. Therefore the best approach is to separately characterize each lesion following the recommendations in R.2.2 and R.2.3.

R.6.1.2 We recommend that all patients with bilateral adrenal incidentalomas should undergo clinical and hormonal assessment identical to that in patients with unilateral adrenal incidentaloma. The same applies for the assessment of comorbidities that might be related to ‘autonomous cortisol secretion’ (Table 2). In addition, 17-hydroxyprogesterone should be measured to exclude congenital adrenal hyperplasia, and testing for adrenal insufficiency should be considered if suspected on clinical grounds or if imaging suggests bilateral infiltrative disease or hemorrhages.

Reasoning:
Hormonal excess in patients with bilateral adrenal masses may originate either from one of the lesions or bilaterally. Cushing’s syndrome, primary aldosteronism, and pheochromocytoma(s) may all be encountered. For the clinical assessment of these entities we refer to guidelines of other societies {Nieman, 2008 #47;Lenders, 2014 #48;Funder, 2008 #276}. As for unilateral lesions, subtle autonomous cortisol secretion is the most common secretory abnormality and, therefore, requires a full assessment of related comorbidities. Occasionally, bilateral adrenal enlargement is due to congenital adrenal hyperplasia and
therefore the additional measurement of 17-hydroxyprogesterone should be performed (Jaresch, 1992 #190). However, the measurement of 17-hydroxyprogesterone to identify the most common cause of congenital adrenal hyperplasia, 21-hydroxylase deficiency, as the cause of bilateral adrenal hyperplasia should be interpreted with caution. In some cases increased levels of 17-hydroxyprogesterone may represent increased secretion of steroid precursors from the lesion(s) (Del Monte, 1995 #191) especially in malignant tumors or in bilateral macronodular adrenal hyperplasia. In these cases low/suppressed ACTH levels may argue against congenital adrenal hyperplasia. Bilateral adrenal enlargement due to metastatic disease rarely causes adrenal insufficiency (for details see R.6.3.6).

R.6.1.3 We suggest that for patients with bilateral incidentaloma the same recommendations regarding the indication of surgery and follow-up are used as for patients with unilateral adrenal incidentalomas.

Reasoning:
‘Autonomous cortisol secretion’ is more frequently encountered in patients with bilateral adrenal incidentalomas, compared to those with unilateral lesions, but there is no published evidence that they should be managed differently. However, in the few cases, in whom bilateral surgery is potentially indicated (e.g. bilateral pheochromocytomas), one can consider adrenal-sparing surgery (Castinetti, 2015 #192).

R.6.1.4 We suggest that in patients with bilateral adrenal masses bilateral adrenalectomy is not performed for ‘autonomous cortisol secretion’ without clinical signs of overt Cushing’s syndrome. In selected patients a unilateral adrenalectomy of the dominant lesion might be considered using an individualized approach considering age, degree of cortisol excess, general condition, comorbidities and patient preference.

Reasoning:
Surgery is a complex decision for patients with bilateral adrenal incidentalomas. This is because, in the absence of clinical signs of overt Cushing’s syndrome, the clinical situation may not be severe enough to prompt surgical management. Moreover, bilateral adrenalectomy is associated with higher morbidity compared to unilateral surgery, the patient is dependent lifelong on adrenal replacement therapy and at risk for life-threatening adrenal crisis. In addition, glucocorticoid replacement is frequently sub-optimal and cannot mimic the
diurnal profile of endogenous cortisol, and may result in persisting exposure to subtle cortisol excess. In bilateral macronodular adrenal hyperplasia there is limited evidence of beneficial effects of unilateral adrenalectomy (Debillon, 2015 #129; Perogamvros, 2015 #213). In most published studies excision of the largest lesion was performed, based on observations that the size of the adrenal lesion correlates with the degree of cortisol excess (Debillon, 2015 #129). Adrenal venous sampling may aid in the lateralization of cortisol excess but the data are very weak (Young, 2008 #302). Due to the limited available evidence, an individualized approach, considering age, degree of cortisol excess, general condition, comorbidity status and patient’s preference is suggested. However, when bilateral surgery is potentially indicated, cortical sparing adrenalectomy might be considered (Vassiliadi, 2011 #195).

In cases of bilateral macronodular hyperplasia, especially in younger patients or those with relevant family history, family screening with 1 mg dexamethasone test can be considered. A number of patients will have evidence of the presence of aberrant receptors, but routine assessment by the complex testing (Vassiliadi, 2011 #197; Bourdeau, 2001 #201; Lacroix, 2009 #199; Lacroix, 2004 #200; Lacroix, 2010 #198; Lacroix, 2001 #202; Libe, 2010 #203; Lacroix, 2015 #140) that is needed to establish the presence of these receptors is hard to justify based on the fact that in the majority of patients long-term management will not be based on knowledge of receptor activity, and therefore we suggest that these tests should be confined to clinical studies.

5.6.2 Adrenal incidentalomas in young or elderly patients

R.6.2.1 We recommend urgent assessment of an adrenal mass in children, adolescents, pregnant women and adults < 40 years of age because of a higher likelihood of malignancy.

R.6.2.2 We suggest the use of MRI rather than CT in children, adolescents, pregnant women and adults < 40 years of age if dedicated adrenal imaging is required.

R.6.2.3 We recommend that the management of patients with poor general health and a high degree of frailty be kept in proportion to potential clinical gain.

Reasoning

The incidence of adrenal incidentaloma shows clear variation with age, with the majority of patients presenting in the 5th to 7th decade of life. Overall incidence of adrenal incidentaloma in a population undergoing routine imaging not related to suspected adrenal disease is reported as 1-4 % (Ferreira, 2005 #128; Bovio, 2006 #45; Hammarstedt, 2010 #126; Davenport, 2011 #125). While 10 % or more of individuals older than 70 years harbor an adrenal mass detectable upon imaging or autopsy, adrenal nodules in individuals < 40
years are much less prevalent and are a rarity in children and young adults. Consequently, work-up in young patients including pregnant women has to be pursued with urgency as the risk of malignancy in this cohort is much higher. Conversely, a smaller adrenal incidentaloma in an elderly patient can be assumed to have a very low pre-test probability of malignancy. Thus work-up in elderly patients only needs to be expedited if there are clear signs of suspicion of malignancy and the extent of imaging work-up should be kept in proportion to the clinical performance status of the individual and the expected clinical gain of further work-up in an affected patient.

As radiation safety is even more important in the young patient, we suggest MRI as the preferred imaging technique. However, adapted low-dose unenhanced CT protocols can limited radiation exposure and can be considered as an alternative (especially if the availability of MRI is limited).

5.6.3 Patients with a newly diagnosed adrenal mass and a history of extra-adrenal malignancy (Figure 4)

General remarks:

In principle, for adrenal masses in patients with known extra-adrenal malignancy the same recommendations apply as described above. However, in this situation it is particularly important to consider the different pre-test probabilities and the life expectancy of the patient.

In patients with underlying extra-adrenal malignancy and an indeterminate adrenal mass, studies revealed a high rate of malignancy, up to 70%. Although age specific subgroup analysis is not available, it can be assumed that older patients have a higher likelihood of co-existent benign adenomas. Conversely younger patients with an underlying malignancy are more likely to have a metastasis.

R.6.3.1 We recommend measurement of plasma or urinary metanephrines to exclude pheochromocytoma in patients with extra-adrenal malignancy with an indeterminate mass, even if the adrenal mass is likely to be a metastasis. We suggest additional hormonal work-up based on an individualized approach.

Reasoning

Pheochromocytomas are almost impossible to distinguish from metastasis by conventional imaging (including FDG-PET/CT). Furthermore, pheochromocytomas can lead to life-threatening complications, especially in the context of medical interventions (surgery,
biopsies etc.) {Mannelli, 2012 #161;Stolk, 2013 #160;Lenders, 2014 #48}. Additional hormonal work-up should depend on the stage of the extra-adrenal malignancy and life expectancy. Evidence of adrenal hormone excess indicating that the mass is a primary adrenal lesion can influence management of the extra-adrenal malignancy.

R.6.3.2 We suggest that in patients with a history of extra-adrenal malignancy FDG-PET/CT, performed as part of investigations for the underlying malignancy, can replace other adrenal imaging techniques.

Reasoning:

18FDG-PETCT may add additional value in the assessment of an indeterminate adrenal mass, however, the evidence base is insufficient to make strong recommendations {Dinnes, 2016 #246}. Both qualitative and quantitative interpretations of 18FDG-PETCT imaging have been studied, but these vary considerably. An adrenal lesion / liver ratio of 1.53-1.8 were investigated in patients with history of extra-adrenal malignancy (2 studies {Kunikowska, 2014 #121;Villar Del Moral, 2010 #104}, 117 lesions) and found to have sensitivity of 82% (95%CI 41-97%) and specificity of 96% (95%CI 76-99%) to detect malignant disease.

R.6.3.3 We recommend that in patients with a history of extra-adrenal malignancy adrenal lesions characterized as benign by non-contrast CT require no further specific adrenal imaging follow-up.

Reasoning

See details R2.2-4. However, we acknowledge that the currently available data suggest a false negative rate of 7% in this population.

R.6.3.4 For indeterminate lesions in patients with a history of extra-adrenal malignancy, we recommend imaging follow-up assessing the potential growth of the lesion at the same interval as imaging for the primary malignancy. Alternatively, FDG-PET/CT, surgical resection or a biopsy (see also R.6.3.5) can be considered.

Reasoning:

In many patients with advanced extra-adrenal malignancy (e.g. with multiple metastases) the knowledge of the origin of the adrenal mass will not alter the clinical management of the...
patient. If, however, clinical management would be altered by the demonstration that the adrenal lesion is a metastasis, then every effort should be made to allow this discrimination. If the adrenal mass is potentially the only metastasis and if resection of this metastasis seems to be reasonable from an oncological point of view, then surgery should be considered. Regarding biopsy, we recommend applying the criteria provided in R.6.3.5.

R.6.3.5 We suggest performing a biopsy of an adrenal mass only if all of the following criteria are fulfilled: (i) the lesion is hormonally inactive (in particular, a pheochromocytoma has been excluded), (ii) the lesion has not been conclusively characterized as benign by imaging, and (iii) management would be altered by knowledge of the histology.

Reasoning:
Adrenal biopsy may present with a significant non-diagnostic rate and a potential for complications {Tamhane, 2016 #248}. Biopsy is only recommended for masses not characterized as benign on cross-sectional imaging and where a biopsy result would affect clinical treatment decisions. In patients with no other obvious metastatic lesions and when surgical removal of the lesion is an option, FDG-PET/CT should be considered in order to exclude metastases outside the adrenal that were not visualized by CT or MRI. Adrenal biopsy presents with lower diagnostic performance for ACC and therefore is not recommended in this setting {Tamhane, 2016 #248}.

R.6.3.6 We recommend assessment of residual adrenal function in patients with large bilateral metastases.

Reasoning
In rare cases, bilateral adrenal metastases can lead to adrenal insufficiency. Thus, in all patients with potentially bilateral metastases, adrenal insufficiency should be considered and clinically evaluated. If adrenal insufficiency seems to be possible, we recommend first to measure a morning serum cortisol and plasma ACTH. In case of adrenal insufficiency, plasma ACTH is clearly elevated in parallel to low cortisol. In uncertain cases, a synacthen test should be performed {Bornstein, 2016 #211}. If only one adrenal metastasis is present, adrenal insufficiency is extremely unlikely and we recommend no specific assessment of adrenal reserve.
Figure 4: Evaluation of patients with adrenal mass and known extra-adrenal malignancy

1 Always take life expectancy in consideration.
2 If there is hormone excess, treat individualized.
3 FDG-PET/CT should be considered to exclude other metastatic deposits in patients with no other obvious metastatic lesions for whom surgical removal of the lesion is an option.
6. Future directions and recommended research

The NIH conference on the management of the clinically unapparent adrenal mass in 2002 formulated several research questions for future studies {Grumbach, 2003 #39}. Although some of these issues have been addressed, only few questions have been conclusively answered. From the current perspective we see need for clinical trials in all four areas particularly addressed in the guideline (see section 3.5). Given that most recommendations in this guideline are based on weak evidence, there is clearly room for studies aiming to improve the evidence base of management of adrenal incidentalomas.

Among many important research questions, we selected five as particularly important. All of them can only be answered in a collaborative interdisciplinary manner.

1) Large, cohort study in patients with an adrenal mass > 2 cm to investigate the most suitable imaging methods to determine if an adrenal mass is benign or not. It will be crucial to establish a definitive diagnosis either by histopathology or by long-term follow-up (> 2 years).

2) Large, long-term study to define whether or not ‘autonomous cortisol secretion’ is associated with increased mortality and other hard clinical endpoints (e.g. myocardial infarction or stroke). Such a study will also provide evidence for a suitable biochemical definition of ‘autonomous cortisol secretion’.

3) Randomized trial on the potential benefit of surgery in patients with "autonomous cortisol secretion". To make such a trial feasible it is probably wise to define a surrogate endpoint (e.g. hypertension or type 2 diabetes) that can be well controlled (including standardized treatment regimens) throughout the study. A similar trial could evaluate the value of drugs targeting the cortisol excess.

4) Prospective study (laparoscopic vs. open surgery) in patients with potentially malignant adrenal mass (<10 cm) without pre-operative evidence of local invasion and metastases to learn which surgical approach is the most suitable one for this patient cohort.

5) We propose a long-term study with annual biochemical work-up of patients with adrenal incidentalomas to clarify if such a long-term hormonal assessment is justified. This study should also help to define the true incidence of relevant diseases like adrenocortical carcinoma and pheochromocytoma among incidentalomas.

Several other research questions deserve future research. Of particular importance seems to us the establishment of biomarkers to determine non-invasively the origin of the adrenal mass (adrenal cortex, medulla, extra-adrenal) and whether or not the mass is malignant. Currently, urine steroid metabolomics for non-invasive and radiation free detection of a malignant 'steroid fingerprint' in adrenocortical carcinoma patients {Arlt, 2011 #34} and the combination of functional imaging methods (e.g. metomidate-based imaging and FDG-
PET/CT) are the most promising tools that should be further investigated. Similarly, for patients with ‘autonomous cortisol secretion’ new methods to stratify on an individual basis to intervention (or observation) are needed.
Acknowledgement

The authors of the guideline would like to thank and acknowledge Andre Lacroix, Radu Mihai, and Paul Stewart for their expert review and additional 28 members of the European Society of Endocrinology, the European Network for the Study of Adrenal Tumors or representatives of national endocrine societies for valuable and critical comments. Furthermore, we thank two patient representatives who provided valuable feedback for the guideline. The comments of the reviewers as well as our responses are available until December 2016 at XXXX (website of ESE).

Funding

This guideline was sponsored by the European Society of Endocrinology with support by the European Network for the Study of Adrenal Tumors (via the European Science Foundation).

Declaration of interest

The guideline was developed in collaboration with CBO – Dutch Institute for Health Care Improvement.
Appendix

Table A1: Description of analyzed studies

Table A2: Results of the GRADE analyses

Table A3: Selected drugs that may interfere with results of the dexamethasone test* (adapted according {Nieman, 2008 #47})

---

**Drugs that accelerate dexamethasone metabolism by induction of CYP 3A4**
- Phenobarbital
- Phenytoin
- Carbamazepine
- Primidone
- Rifampin
- Mitotane
- Rifapentine
- Ethosuximide
- Piflglitazone

**Drugs that impair dexamethasone metabolism by inhibition of CYP 3A4**
- Aprepitant/fosaprepitant
- Itraconazole
- Ritonavir
- Fluoxetine
- Diltiazem
- Cimetidine

**Drugs that increase CBG and may falsely elevate cortisol results**
- Estrogens
- Mitotane

---

* This should not be considered a complete list of potential drug interactions.

Data regarding CYP3A4 obtained from http://medicine.iupui.edu/flockhart/table.htm.